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Abstract 
Effectiveness of Biofeedback in Improving Heart Rate Variability 
Recovery Following Stress 
 
Amanda L. Wheat 
 The current study was designed to examine the efficacy of heart rate variability (HRV) 
biofeedback using emWave, a specific biofeedback device available to the public, and to 
determine whether such treatment affects phasic physiological responses to stress. Twenty-seven 
individuals (4 males, 23 females), aged 18-30 years (M = 22.54 years, SD = 3.82) participated in 
the current study. Thirteen individuals were randomly assigned to a control group and received 
no intervention, whereas the remaining 14 participants underwent 4-8 sessions of emWave 
intervention. All participants attended pre-treatment and post-treatment assessment sessions 
during which a stressor protocol was administered; physiological data were collected during rest, 
during stress, and following stress. EmWave treatment did not confer changes in resting, or 
tonic, measures of HRV. However, participants who received emWave treatment exhibited 
higher parasympathetic responses (i.e., pNN50) during stress at the post-treatment session 
compared to their control counterparts. Significant group differences in HRV were not evident 
during the post-stress recovery period. Additionally, no treatment effects were evident on self-
reported measures of stress, psychological symptoms, or affect administered during the pre- and 
post-treatment assessment visits. Overall, results from the current study, combined with previous 
literature, suggest that the emWave may confer some limited treatment effects by increasing 
HRV in response to stress. Additional development and testing of the emWave treatment 
protocol is necessary before it can be recommended for regular use in clinical settings, including 
the determination of what physiological changes occur during HRV biofeedback that contribute 
to any clinical effects that may occur with the emWave treatment. 
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1. Introduction 
Knowledge of interplay between physiological and psychological phenomena, and how 
those phenomena might be manipulated to promote health, have been persistent areas of growth 
in both medical and psychological fields of study since the inception of psychophysiology and 
behavioral medicine. For example, the last three decades have encapsulated progress discerning 
how various physiological and psychological factors affect each other, such as the interplay 
between amygdala activity and emotion (e.g., Phelps, 2006), cortisol and stress (e.g., Taylor, 
Burklund, Eisenberger, Lehman, Hilmert, Lieberman, 2008), cardiovascular reactivity and fear 
(e.g., Lerner, Dahl, Hariri, & Taylor, 2007), and dopamine and temperament (e.g., Schmidt, Fox, 
Perez-Edgar, & Hamer, 2009), among many others. Heart rate variability (HRV) is one of the 
newest physiological parameters that have gained attention in such a context (e.g., Shea, Kamath, 
Fleming, Streiner, Redmond, & Steiner, 2008). In brief, HRV refers to oscillations in heart rate 
that occur naturally. Such fluctuations can be seen from beat to beat and reflect communication 
between the brain and the heart, as influenced by traffic within the sympathetic and 
parasympathetic nervous systems. The investigation of HRV is unique and important because it 
incorporates the influence of the cardiovascular and neurological systems whereas areas of 
interest in psychophysiology have typically focused on singular physiological systems (e.g., 
endocrine, cardiovascular, or reproductive systems).  
HRV originally was considered to be error variance that prevented researchers from 
discerning valid signals of cardiac activity (Lehrer, 2007). However, knowledge of physiological 
processes evolved to reveal HRV’s value as a variable of independent interest. The magnitude 
and complexity of HRV are now known to reflect important avenues for examining autonomic 
nervous system functioning, and low HRV has been linked to increased susceptibility to stress 
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and disease (e.g., Bigger, Fleiss, Rolnitzky, & Steinman, 1993; Carpeggiani et al., 2004; Griffin, 
Lake, Bissonette, Harrell, O’Shea, & Moorman, 2005; Kim et al., 2005). Measures of HRV 
reflect several mechanisms working in concert to maintain a healthy level of cardiovascular as 
well as neural activity. When these systems are not functioning at an optimal level, an 
individual’s stress response may be more severe. The consequence is a more deleterious effect of 
stress that may contribute to physical or psychological illnesses, such as cardiovascular disease, 
metabolic syndrome, depression, and anxiety (McGrady, 2007). It follows that obtaining and 
maintaining a healthy range of HRV would better equip individuals to manage stress and 
potentially reduce risk for or severity of numerous stress-related diseases. 
In relatively recent years, investigators have drawn attention to the potential prognostic 
value of HRV due to relations between diminished HRV and several health problems. For 
example, diminished HRV has been shown to be predictive of all-cause mortality, sudden 
cardiac death, and other complications in patients who experienced myocardial infarction 
(Bigger et al., 1993; La Rovere, Bigger, Marcus, Mortara, Schwartz, 1998). Diminished HRV 
also has been documented in individuals with hypertension (Schroeder, Liao, Chambless, 
Prineas, Evans, & Heiss, 2003), fibromyalgia (Martínez-Lavín, Hermosillo, Rosas, & Soto, 
1998), HIV and AIDS (Correia et al., 2006), and diabetic neuropathy (Boysen, Lewin, Hecker, 
Leichter, & Uhlemann, 2007), among other medical conditions. 
Psychological disorders or symptoms have also been investigated in relation to 
diminished autonomic activity. Several studies have found evidence for an association between 
depressive symptomology and low HRV (Agelink, Boz, Ulrich, & Andrich, 2002; Yeragani, 
Roa, Smitha, Pohl, Balon, & Srinivisan, 2002). A significant relation also was reported between 
anxiety and sensitivity of baroreflexes (Watkins, Blumenthal, & Carney, 2002). Patients 
HRV Biofeedback      3  
diagnosed with generalized anxiety disorder (Thayer, Friedman, & Borkovec, 1996), panic 
disorder (Cohen, Benjamin, Geva, Matar, Kaplan, & Kotler, 2000), and post-traumatic stress 
disorder (Cohen, Kotler, Matar, & Kaplan, 1997; Cohen et al., 2000) also have been reported to 
exhibit low HRV. 
Given the potential salutary effects of increasing HRV, it is important to understand how 
HRV may be changed. Prerequisite to that understanding, however, is knowledge of key factors 
involved in the measurement and physiological components of HRV. Although several methods 
may be used to quantify HRV (see Task Force, 1996 for a review), one of the most often used is 
a frequency method known as power spectral density analysis. Such analysis allows the 
separation of overall HRV into its distinct, composite frequency components that are each known 
to be associated with certain types of autonomic activity (see Figure 1). Even before the 
popularization of HRV as an investigatory topic, the basic contributors to each frequency 
component were identified. Generally, low frequency HRV was shown to be associated with  
 
Figure 1. Power spectral density analysis graph. Waveform components between .05 and .15 Hz (depicted at the far 
left) reflect low frequency HRV and waveform components between .15 and .40 Hz reflect high frequency HRV.  
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both sympathetic and parasympathetic activity, whereas high frequency HRV was linked 
predominantly to parasympathetic function (Akselrod, Gordon, Ubel, Shannon, Berger, & 
Cohen, 1981). More details regarding each of these frequency components and their constituent 
physiological factors follows. 
As a component of the parasympathetic nervous system, the vagus nerve innervates the 
heart’s sinoatrial node, which is responsible for controlling heart rhythm (Berntson et al., 1997). 
During exhalation, the vagus nerve activates and causes heart rate (HR) to decrease, whereas 
inhalation causes inhibition of vagus nerve activity, disallowing vagally-mediated decreases in 
HR. Although there is a slight delay between respiration and change in HR during normal 
breathing, HR systematically varies with respiration, a phenomenon called respiratory sinus 
arrhythmia (RSA). Variation in HR occurs over a range of frequencies, and resting levels 
of RSA occur in the high frequency bandwidth of spectral waveform analysis (0.15-0.40 Hz) 
(Berntson et al., 1997; Lehrer, 2007). RSA has been suggested as a marker of parasympathetic 
(i.e., vagal) tone, and high frequency HRV therefore is considered to reflect vagal tone. 
However, because the sinoatrial node is influenced sympathetically as well, caution is merited in 
interpreting high frequency HRV as an unmitigated measure of vagal tone. 
In addition to the high frequency range (0.15-0.4 Hz), there also is a low frequency 
bandwidth in which HRV is measured (0.05-0.15 Hz)
2
 (Berntson et al., 1997; Lehrer, 2007). 
Whereas parasympathetic tone is commonly associated with high frequency HRV, low frequency 
HRV is reported to reflect activity of both autonomic branches. The role of baroreceptors in 
HRV is typically thought to influence the low frequency range. Located in both the aortic arch 
and carotid sinus, baroreceptors exhibit reflex action in response to changes in blood pressure 
(BP) to counter sudden or extreme BP fluctuations (Berntson et al., 1997). When increases in BP 
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are detected, the resulting baroreflex causes decreases in HR, which leads to decreases in BP. 
Conversely, baroreceptors respond to low BP by inducing increases in HR, which effectuate 
increases in BP. Increases or decreases in low frequency HRV are thought to be a result of (a) 
changes in baroreflexes that follow changes in BP, or (b) increased or decreased baroreceptor 
sensitivity. Baroreflexes are also thought to confer resonant properties on the cardiovascular 
system (Lehrer, 2007; Vaschillo, Vaschillo, & Lehrer, 2006). Paced rhythmic breathing at a 
specific, individualized rate (≈ 6 breaths per minute, 0.1 Hz) provides stimulation that causes HR 
and respiration to be exactly synchronized. Maximization of HRV and RSA is only achievable at 
this resonance frequency, which is the result of maximally efficient interactions between 
respiration, baroreflex activity, BP, and HR. This process is also considered to exercise the 
baroreflexes, making them generally more effective and responsive to changes in the internal and 
external environment.  
In addition to high and low frequency HRV (i.e., frequency domain measures), HRV may 
also be quantified with time domain methods (Task Force, 1996). Some investigations of HRV 
examine both time and frequency domain outcomes (e.g., Del Pozo, Gevirtz, Scher, Guarneri, & 
2004; Hallman, Olsson, von Scheele, Melin, & Lyskov, 2011; Karavidas et al., 2007). Although 
several time domain HRV outcomes exist (Task Force, 1996), many overlap in the physiological 
systems whose activity they reflect, so not all are discussed here. Briefly, standard deviation of 
normal sinus to normal sinus intervals (also called NN intervals) (i.e., SDNN) comprises all 
components of HRV and reflects the total power of spectral analysis. Therefore, it serves as a 
measure of overall HRV. However, several time domain measures are more reflective of 
parasympathetic activity than sympathetic activity (e.g., pNN50 and RMSSD).  pNN50 is the 
percentage of successive NN intervals that are greater than 50 ms, and RMSSD (in ms) is the 
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square root of the mean of the squared differences of successive NN intervals. Both of these time 
domain parameters may be utilized, along with high frequency HRV, to measure 
parasympathetic influence (Task Force, 1996). 
Studies have shown that compromised HRV, measured using both time and frequency 
based methods of assessment, pervades several undesirable physical and mental health 
conditions (see Wheat & Larkin, 2010). As a marker of decreased autonomic health, restricted 
HRV may play a significant role in conveying risk for perseveration, if not worsening, of 
symptoms in a wide range of psychological and physical disorders as well as all-cause mortality. 
Given the potential role of reduced HRV reflecting a physiological mechanism through which 
psychological factors affect health, an important avenue of scientific inquiry is to identify 
effective treatments for increasing HRV. One promising method of intervention is using HRV 
biofeedback. 
1.1 Heart Rate Variability Biofeedback 
Although biofeedback has been used for many years to modify a broad range of 
physiological processes, it recently has been implemented as a method for changing HRV and/or 
baroreflexes. Biofeedback involves (a) increasing awareness and/or self-regulation of 
physiological activity (b) via measurement of physiological activity and provision of 
corresponding visual or auditory feedback (Schwartz & Schwartz, 2003). Although the 
application of biofeedback to HRV is recent, biofeedback itself has a longer history. Research in 
the 1960s and 1970s showed that autonomic processes were not beyond voluntary control and 
could be conditioned instrumentally (e.g., LeFevers, 1971; McCanne & Sandman, 1974; 
Schoenfeld, Matos, & Snapper, 1967). In combination with that knowledge, the emergence of 
behavioral medicine, emphasis on stress and stress management research, advancement in 
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physiological measurement, and other historical factors set the stage for research in various 
forms of biofeedback and its clinical applications. Older forms of biofeedback (e.g., HR, BP) 
focused on achieving a level, rather than altering the variability, of an aspect of physiology 
(Lehrer, 2007). Older methods of biofeedback also were less comprehensive in improving 
cardiovascular regulation than HRV biofeedback. For example, whereas BP biofeedback 
addresses improvement of BP regulation directly, likely through indirect effects on other 
parameters (e.g., HR regulation), HRV encompasses the interaction of several individual 
cardiovascular processes. Its biofeedback involves the broader mechanism of homeostasis within 
both cardiovascular and neural systems. 
Although HRV biofeedback is a relatively new area, several studies lend support to the 
proposition that such treatment is effective in improving HRV. Most studies implemented a 
manualized HRV biofeedback protocol developed by Lehrer et al. (2000), during which the goal 
is to locate participants’ resonant frequency and have them practice attaining and maintaining 
resonant frequency via breathing at the rate at which such resonance occurs (~0.1 Hz, low 
frequency range). Such practice is believed to exercise the baroreflexes and improve HRV, 
thereby conveying beneficial health effects. Investigations of HRV biofeedback show that 
increases in low frequency HRV occur during biofeedback (Hassett et al., 2007; Karavidas et al., 
2007; Lehrer et al., 1997; Lehrer et al. 2003; Lehrer et al., 2004; Lehrer et al., 2006). 
 Although most research studies share that common method of HRV biofeedback, there 
has been a relatively recent appearance of alternative modalities of biofeedback that are 
functionally similar in methods and/or objectives (e.g., Amon & Campbell, 2008; Heilman, 
Handelman, Lewis, & Porges, 2008; McCraty, Atkinson, & Tomasino, 2003; Muench, 2008). 
The potential for such newer modalities to be utilized clinically for issues such as anxiety, stress 
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management, or hypertension, etc., is great, especially considering their affordability. The 
programs also target lay persons and various health professionals as consumers and therefore are 
user friendly. However, there is a paucity of research dedicated to discerning whether 
biofeedback treatment with these instruments confers any improvement in HRV.  
The emWave (formerly Freeze Framer, HeartMath Institute, Boulder, CO) is one such 
product that currently is marketed for use as biofeedback treatment. To this author’s knowledge, 
no data exists indicating how many and what types (e.g., healthcare provider vs. 
layperson/personal consumer) of individuals or companies are utilizing emWave or related 
products from HeartMath. It is available to the public for purchase on the worldwide web. 
Whereas the protocol utilized in traditional HRV biofeedback studies emphasize breathing at the 
resonance frequency to produce a ~0.1 Hz peak, treatment with the emWave focuses on training 
induction of positive emotional states that are associated with ‘psychophysiological coherence,’ 
as termed by its creators at the HeartMath Institute (McCraty, Atkinson, Tomasino, & Bradley, 
2006). The coherent state is characterized in the following way:  
The development of heart rhythm coherence—a stable, sine-wave-like pattern in 
the heart rate variability waveform—is the key marker of the psychophysiological 
coherence mode. Heart rhythm coherence is reflected in the HRV power spectrum 
as a large increase in power in the low frequency (LF) band (typically around 0.1 
Hz) (p. 8).  
McCraty and colleagues propose that emotional training is preferable to breathing training due to 
the effort required to maintain paced breathing at a specified rate for an extended time period. 
Therefore, although the biofeedback methods differ, it is clear that emWave training embodies 
biofeedback session goals that functionally are similar to those implemented in historical HRV 
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biofeedback research. In fact, the visual biofeedback of HRV that is provided with the emWave 
software is strikingly similar to that which is provided with software utilized by HRV 
biofeedback researchers (e.g., Lehrer et al., 2003). Further, McCraty et al. directly equate their 
concept of coherence with what “[Lehrer] calls ‘resonance’” (p. 23). Further, calculation of 
coherence utilizes information derived during power spectral density analysis of HRV (see 
Figure 2). In brief, the coherence ratio is the proportion of the waveform immediately 
surrounding the peak of the spectral density analysis to the remaining components of the 
waveform. High coherence ratios indicate that one’s heart rhythm occurs consistently within the 
frequency band that surrounds the peak waveform, as depicted in Figure 2. In contrast, low 
coherence ratios are depicted by a broader display of frequencies in the spectral waveform.  
 
Figure 2. Utilization of power spectral density data to calculate the emWave’s coherence ratio. Figure taken from 
McCraty et al. (2006). 
It may be reasonably expected then that coherence training received through biofeedback 
with the emWave should produce improvement in HRV, if the training is effective. However, no 
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study has been conducted specifically to validate the emWave as a tool for improving HRV via 
biofeedback. In fact, many interventions have implemented the emotional management 
techniques of the emWave or Freeze Framer programs without implementing biofeedback at all. 
Results of these studies indicated that treatment without the biofeedback component resulted in 
increased positive affect, positive attitudes, and total HRV (but not low or high frequency HRV), 
as well as reductions in stress, anxiety symptoms, depression symptoms, hostility, and salivary 
cortisol (Barrios-Choplin, McCraty, & Cryer, 1997; Luskin, Reitz, Newell, Quinn, & Haskell, 
2002; McCraty, Barrios-Choplin, Rozman, Atkinson, & Watkins, 1998; Rozman, Whitaker, 
Beckman, & Jones, 1996; Barrios-Choplin, McCraty, Sundram, & Atkinson, 1999). Some 
studies have incorporated the biofeedback component as well. Those studies showed that 
treatment resulted in increased workplace satisfaction, positive affect, positive attitudes, and 
peacefulness, as well as reductions in areas such as stress, symptoms of anxiety, symptoms of 
depression, social inhibition, negative affect, anger, fatigue, sleeplessness, and blood pressure 
(Barrios-Choplin et al., 1999; Climov, 2008; McCraty, Atkinson, Lipsenthal, & Arguelles, 2003; 
McCraty et al., 2003b; McCraty, Atkinson, Tomasino, Goelitz, & Mayrovitz, 1999; McCraty, 
Tomasino, Atkinson, Aasen, & Thurik, 2000). Of the studies incorporating biofeedback, only 
two studies assessed HRV as an outcome. One study failed to find significant differences in 
HRV following treatment (McCraty et al., 2003a), whereas results of the other study indicated 
that middle school students receiving treatment, but not those students in a control group, 
exhibited increased HRV during recovery from a stressor following treatment (McCraty et al., 
1999). It is difficult to make conclusions on the efficacy of the emWave program in improving 
HRV for several reasons. First, the results of studies that assess HRV are contradictory. Second, 
each of the studies suffered from serious limitations (e.g., contamination of control group, 
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optional nature of biofeedback), thereby reducing confidence in their respective results. More 
generally, most investigations of techniques involved in the emWave program—emotion 
management training, biofeedback, or both—involved serious limitations that preclude 
confidence in the effectiveness of the program. These issues include, but are not limited to, lack 
of a control group, embedding of emWave components within a larger set of treatment 
techniques, variation within studies of treatment delivery (e.g., some participants undergo more 
extensive treatments or more treatment components than others).  
Validation of the emWave’s capacity to confer improvement in HRV, and whether those 
changes correlate with coherence, would lend credibility to the emWave as an affordable tool for 
use in improving HRV, which is a marker of physical and mental health, as outlined previously. 
Third-party validation is important with the emWave because the majority of research 
surrounding its use has been produced by the HeartMath Institute and/or its members. In fact, a 
portion of the research is published through the HeartMath Institute rather than peer-reviewed 
journals. 
Another limitation of studies investigating treatment effects of the emWave, congruent 
with the biofeedback literature in general, is the tendency to focus on altering tonic physiological 
levels rather than phasic physiologic responses. Tonic levels of a given physiological parameter 
refer to resting levels of that parameter, whereas phasic levels refer to measures of the given 
parameter in response to a physical or psychological challenge.  If indeed the emWave is 
intended to make coherence/resonance easier to achieve within the context of stress (McCraty et 
al., 2006), studies of its efficacy need to employ both tonic and phasic measures of HRV as 
outcome variables. Despite the conception that improvements in HRV may serve to buffer the 
effects of stress on the cardiovascular system, only one traditional HRV biofeedback study and 
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one emWave study have examined whether HRV biofeedback treatment would result in 
improved phasic HRV responses to stress (McCraty et al., 1999; Nolan et al., 2005). In the 
traditional HRV biofeedback study, patients with coronary heart disease were randomized to a 
treatment or active control group (i.e., treatment as usual) (Nolan et al., 2005). The authors 
proposed that the HRV biofeedback treatment would result in increased parasympathetic 
recovery from stressors, as indicated by increased high frequency HRV during recovery. At post-
treatment, the treatment group exhibited increases in high frequency HRV following one of three 
stressors and during the final recovery period following all stressors. No such significant 
increases were observed during any recovery period in the control group. Therefore, following 
the experience of vagal inhibition (i.e., decreased HRV) during stress, HRV biofeedback 
appeared to effectuate increases in high frequency HRV, indicating improved vagal recovery 
from stress. 
Nolan et al.’s (2005) investigation suffered from shortcomings, however. For example, 
participants in the treatment group underwent HRV biofeedback after experiencing all 
components that the active control received (e.g., autogenic relaxation training, pleasant events 
scheduling). Therefore, it is possible that significant improvements in HRV recovery following 
stress were due to a combination of the two protocols rather than to HRV biofeedback alone. In 
addition, approximately 18% of the total sample was excluded from analyses due to exhibition of 
HRV during recovery at a frequency that was characteristic of slow, paced breathing, which they 
were instructed not to do. Although necessary for analytical purposes, such elimination may 
affect the validity of the results as those participants’ may have differed from subjects whose 
data were analyzed regarding their cardiovascular responses to treatment or active control 
protocols. Potential cardiovascular differences between those who were and were not excluded 
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for that reason were not analyzed. Finally, coronary heart disease patients can reasonably be 
expected to vary from healthy subjects in cardiovascular profiles and responses. Therefore, the 
study results cannot be generalized to healthy individuals.  
The emWave study that implemented a stressor protocol involved middle-school student 
participants who were enrolled in a course in emotional competence (“Heart Smarts”) (McCraty 
et al., 1999). The course aimed to increase the participants’ ability to cope appropriately with 
stress during situations that were emotionally challenging, and training with the emWave was 
one part of the course. A subset of participants was selected to participate in a stress recovery 
protocol following treatment, and the treatment group was instructed to use the emWave 
techniques they learned during the recovery period that followed the stressor. The treatment and 
control groups did not differ in HRV during baseline or during the stressor. During recovery, 
however, the treatment group exhibited higher total and LF HRV than the control group.  
Similar to the previously described study that used a stress reactivity protocol, McCraty 
et al.’s (1999) study exhibited significant flaws. Most importantly, biofeedback was offered to 
the students as part of the treatment, but was not mandatory. No analyses were performed to 
separate those who did and did not utilize the biofeedback component. Therefore, it is impossible 
to determine to what extent biofeedback was implemented and how it affected HRV outcomes. 
In a related vein, the techniques involved in the emWave/Freeze Framer portion of the program 
were included within a year-long course that taught additional skills that may have contributed to 
the outcome independent of the emotional management portion of treatment. Therefore, given 
the near absence of research investigating HRV outcomes in the context of stress reactivity 
protocols and the quality of the two studies that have been performed, the need to determine 
whether biofeedback improves reactivity to and recovery from stressors is evident.  
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2. Goals and Significance of the Proposed Study 
 Due to the absence of research investigating whether biofeedback treatment with the 
emWave results in physiological regulation as indexed by HRV, the first goal of the proposed 
study was to determine whether such effects exist. Because improved HRV should serve to 
mitigate the effects of stress, thereby purportedly conveying decreased risk for development, 
worsening of, or complications following physical and psychiatric illness, the second goal of the 
proposed study was to determine whether reactivity to and recovery from a stressor improve 
following treatment with the emWave. Therefore, the following research questions were 
proposed: 
1. Does HRV biofeedback treatment with the emWave effectuate increases in tonic HRV? 
2. Does HRV biofeedback treatment with the emWave confer improvement in HRV 
reactivity during a stressor? 
3. Does HRV biofeedback treatment with the emWave result in differences in HRV 
recovery after a stressor? 
Answering these questions may address the following shortcomings that currently 
demand empirical attention in HRV biofeedback literature. Although used in full or in part in 
several empirical endeavors, biofeedback treatment with the emWave has not been subject to 
analytical scrutiny regarding its effects on HRV. No study exists to the author’s knowledge that 
specifically aimed to validate the emWave for conveying improvement in HRV. Although 
several studies that utilized the emWave in some fashion have analyzed HRV outcomes, those 
investigations (1) were performed primarily to address questions that did not involve HRV, and 
(2) exhibited significant flaws that prohibit determination of whether the emWave was 
responsible for conferring improvements in HRV when they were present. Further, HRV 
HRV Biofeedback      15  
biofeedback treatment is believed to be beneficial because it improves functioning in the 
cardiovascular system, ultimately resulting in partial mitigation of the stress response and its 
health-related consequences. Although limited attempts have been made to discern whether HRV 
biofeedback treatment results in improved cardiovascular responses to a stressor, the attempts 
were unsystematic and limited by several methodological weaknesses. The occurrence or 
absence of such a phenomenon, given the implication of related findings to the rationale for 
HRV biofeedback, deserves attention as a primary research objective. If treatment with the 
emWave can systematically be shown to provide improved tonic and/or phasic HRV outcomes, a 
valuable clinical resource that is both affordable and easily utilized may emerge for 
implementation in the future with a reliable evidence base. 
The current project is particularly timely considering the ongoing difficulty that 
practitioners face in procuring reimbursement for biofeedback treatments (HRV and otherwise) 
(e.g., Shaffer, Neblett, & Crawford, 2008). As the struggle for securing reimbursement 
continues, efforts to discern which treatments are effective and affordable are imperative. The 
current project was one such effort. 
3. Method 
3.1. Study Personnel and Timeline 
 Amanda Wheat, a doctoral candidate in the Department of Psychology at West Virginia 
University, conducted the study. Ms. Wheat’s qualifications to conduct the study include a 
Master’s degree in Psychology and three years of research involvement in the Behavioral 
Physiology Laboratory at West Virginia University. Data collection began during the Spring 
2010 semester, and the data collection phase was completed during the Fall 2010 semester. Ms. 
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Wheat assumed primary responsibility for conducting laboratory sessions described in this 
proposal, including overseeing one undergraduate and one graduate student research assistant.    
3.2. Participants   
Twenty-eight undergraduate and graduate student participants at West Virginia 
University were recruited via psychology classes using the SONA system (undergraduate 
students) and e-mail contact (graduate students). Participants were excluded if they smoked or 
used smokeless tobacco, had chronic major health problems (e.g., heart disease, cancer), or if 
they were on drug regimens that directly influenced heart rate and/or blood pressure (e.g., beta 
blockers). Participants received extra credit and/or cash for their participation, which varied 
based on the length of their participation (e.g., six sessions vs. eight sessions), nature of their 
participation (i.e., treatment vs. control group), and/or student status (undergraduate vs. 
graduate).  Of an original pool of participants completing the online screening survey (N = 325), 
77 respondents were contacted via e-mail to participate in the lab-based portion of the study. 
Twenty-eight participants initiated participation in the study, and 27 (96.4%) completed the 
study. A flow diagram in Figure E1 based on CONSORT 2010 recommendations (Schulz, 
Altman, & Moher, 2010) provides further information regarding recruitment of the study sample. 
As no HRV biofeedback studies existed at the time of study development and 
implementation with the same design and/or analytical strategy as the proposed study, it was 
difficult to estimate an effect size to determine appropriate sample size. Sample sizes in HRV 
biofeedback studies whose results showed short-term changes in HRV range widely, although 
some authors reported significant HRV results with small samples. Lehrer et al. (1997) utilized 
17 participants in a three-group treatment design, whereas Hassett et al. (2007) and Karavidas et 
al. (2007) implemented open-label treatment studies without control groups with 12 and 11 
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participants, respectively. Each of those studies found significant improvement in one or more 
HRV outcomes. It should be recognized that those changes were not evident from pre-treatment 
to post-treatment, which is common across such traditional HRV biofeedback studies. However, 
because significant HRV findings were present, it is unlikely that the analyses were 
underpowered. It seems more likely that the treatment protocol implemented in those studies was 
not configured as it stood to support long-term pre-treatment to post-treatment improvements. 
Treatment with the emWave may better confer such outcomes. Therefore, the current study’s 
aim was inclusion of twenty-four participants, and 28 participants enrolled. Although analyses 
including as few as 11-17 participants resulted in significant findings, collecting data for a few 
more participants appeared reasonable to increase likelihood of sufficient power for detecting 
treatment effects. 
3.3. Experimental and Analytical Design 
Recruited participants were randomly assigned to either the treatment or control group. 
At pre-treatment, both groups participated in a stress reactivity protocol during the initial lab 
visit. The treatment group then received a PC-based biofeedback treatment across several lab 
visits. All participants then underwent a post-treatment assessment identical to the pre-treatment 
assessment. A mixed factors Group (Treatment, Control) by Session (Pre-Treatment, Post-
Treatment) research design was employed, with Group serving as between subjects factor and 
Session as the repeated measures factor. 
3.4. Measures 
3.4.1. Demographics. Participants completed a demographics questionnaire including 
items related to participant characteristics (e.g., age, sex), health behaviors (e.g., exercise, 
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smoking), health problems (e.g., chronic illness), and medications known to have cardiovascular 
effects that could confound HRV data (see Appendix A).  
3.4.2. Heart Rate Variability. HRV was measured using HR data gathered with a Polar 
(Lake Success, New York) RS800CX heart rate monitor. Data obtained from the Polar monitor 
have been shown to correlate highly and significantly with ECG-derived measures of HR during 
rest periods and during performance of stressful tasks (Goodie, Larkin, & Schauss, 2000). This 
device functions by transmitting ECG signals from a sensor strapped around the participants’ 
chest to a wristwatch in an adjoined room. Via a USB device, the wristwatch was wirelessly 
connected to a computer where data collection was monitored real-time by the experimenter.  
3.4.3. Self-report Measures. Self-report measures of psychological symptoms and 
distress were included for purposes of comparing results relevant to these outcomes with 
previous studies implementing emWave training to some extent that used the same (or similar) 
measures. Additionally, state affect was measured to supplement measures of physiological 
indices of reactivity and recovery. 
The Brief Symptom Inventory (BSI; Derogatis, 1993) provided a global measure of 
distress (i.e., Global Severity Index) and nine specific subscale scores (i.e., Somatization, 
Obsessive-compulsive, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic 
Anxiety, Paranoid Ideation, Psychoticism). Participants responded to 53 items on a 5-point 
Likert-type scale to indicate intensity/distress related to various symptoms. The BSI exhibits 
adequate internal consistency, test-retest reliability, and convergent and construct validity 
(Derogatis & Melisaratos, 1983). Further, correlations with the Symptom Checklist-90, the 
parent form of the BSI, were shown to be high. Following are Cronbach’s alpha values for the 
BSI subscales in the current study: Somatization (pre-test: 0.73; post-test: 0.79), Obsessive-
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compulsive (0.86; 0.90), Interpersonal Sensitivity (0.76; 0.83), Depression (0.82; 0.86), Anxiety 
(0.76; 0.84), Hostility (0.73; 0.68), Phobic Anxiety (0.64; 0.90), Paranoid Ideation (0.72; 0.80), 
and Psychoticism (0.50; 0.62). On average, Cronbach’s alpha for pre-test subscales was 0.72, 
and for post-test subscales was 0.80. Cronbach’s alpha for the Global Severity Index at the pre-
test session was 0.95, and was 0.96 at the post-test session. 
The Perceived Stress Scale (PSS) indexed stress with 14 items rated on a Likert-type 
scale (Cohen, Kamarck, & Mermelstein, 1983). Participants indicated how often they had certain 
experiences in the previous month (e.g., “How often have you felt that you were on top of 
things?”). Sufficient alpha coefficient reliabilities (i.e., ≈ 0.85) have been demonstrated with the 
PSS, and PSS scores also were shown to correlate significantly with life event and depressive 
symptom scores. Cronbach’s alphas for the current study for the scale at pre-treatment and post-
treatment were 0.88 and 0.89, respectively. 
Finally, the Multiple Adjective Affect Checklist – Revised (MAACL-R; Zuckerman & 
Lubin, 1985) measured state affect during the stress reactivity protocol. The MAACL-R contains 
five subscales: Anxiety, Depression, Hostility, Positive Affect, and Sensation Seeking. 
Participants indicated which of 66 adjectives described how they felt at baseline and during each 
stressor. Validity and reliability have shown to be satisfactory for an earlier version of the 
instrument, and subscales of the currently proposed and earlier version were high (Lubin, Van 
Whitlock, Reddy, & Petren, 2001). Further, all subscales have been shown to have high internal 
consistency, with an averaging .88 across subscales. As the MAACL-R was administered three 
times (i.e., rest, reactivity, recovery) at the two assessment sessions (i.e., pre-test and post-test), 
internal consistency was computed 6 times for each subscale for the current study. Kuder-
Richardson values were: Anxiety (range = 0.22-0.81; average = 0.49), Depression (0.36-0.78; 
HRV Biofeedback      20  
0.58), Hostility (0.46-0.75; 0.67), Positive Affect (0.50-0.86; 0.69), and Sensation Seeking (0.14-
0.68; 0.47). It should be noted that low internal consistency values are likely reflective of the 
small sample and low variance due to many or all participants endorsing few items, or sometimes 
none, at some points of measurement. 
3.5. Procedure 
Following their provision of informed consent, participants completed a demographic 
measure online to obtain standard information (e.g., age, gender) and to garner sufficient data 
about health issues so exclusion of ineligible participants occurred prior to inviting qualified 
participants to the lab. Participants were randomly assigned to treatment or control groups using 
a list of odd or even numbers from a random number table. After randomization, participants 
attended a lab session during which the pre-treatment stress reactivity assessment occurred, 
which is described below. Following the pre-treatment assessment, participants completed 
activities corresponding to their group assignment. When such activities were completed, as 
outlined below, a post-treatment assessment occurred that mirrored the pre-treatment assessment.  
3.5.1. Stress Reactivity Protocol. During the first lab visit, participants completed 
consent and HIPAA authorization forms, at which time their participatory role in the study was 
explained. The experimenter collected height and weight data in addition to assessing for 
alcohol, caffeine, and nicotine use within the past two hours via self-report. Engagement in 
vigorous exercise was assessed at that time also. Participants denied engaging in such activities 
within two hours of session attendance, so none were excluded from the study or rescheduled for 
later participation. Before physiological assessment, participants completed self-report measures. 
Participants then equipped themselves with the Polar monitor in the absence of the experimenter, 
and the experimenter tested accurate placement of the Polar by examining data transmission to 
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the computer. Participants were instructed to remain seated in a chair and to remain relatively 
still with feet flat on the floor while HR data were collected during a 15-minute rest period. Data 
from the final 5 minutes of the rest period were used in analyses. Following completion of the 
rest period, but before the first stressor, participants completed the first MAACL-R. 
Participants then underwent a stress reactivity protocol. Specifically, a mental arithmetic 
task required that the participant count aloud and backward from 9,000 in increments of seven. 
Participants were encouraged to continue from the last place they remembered if they lost track 
of counting during the task. The task was five minutes in length. Following the mental arithmetic 
task, there was a five-minute recovery period during which they completed the second MAACL-
R. After the recovery period, participants engaged in an isometric hand-grip task (Lafayette 
Instruments hand dynamometer model 78010, Lafayette, USA). The investigator assessed 
participants’ maximum grip strength, and the participants were instructed to maintain 30% of 
that grip strength for 3 minutes. Again, another five-minute recovery period followed, and 
participants completed the third and final MAACL-R at that time.  
3.5.2. Treatment Protocol. The emWave PC Stress Relief System (“emWave,” 
HeartMath, LLC, Boulder, Colorado) provided HRV biofeedback treatment. The emWave 
includes a fingertip plethysmograph that transfers heart rate data to a software program through 
which biofeedback is provided. Data from the sensor is transformed to display participants’ heart 
rhythm in real time. In addition, graphs depicting the HRV power spectrum or pulse wave were 
displayed. The third biofeedback component involves coherence. There are three bars of varying 
colors, and each responds to low, medium, or high coherence levels. This visual biofeedback 
provided information to the participant to assist in physiological and emotional self-regulation 
while they implemented the quick coherence technique taught with emWave (see below). 
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 Following their initial assessment, participants in the treatment group worked with the 
experimenter to customize a schedule for biofeedback training. HRV, HRV biofeedback, and 
how HRV is related to health were explained at the first biofeedback visit. In addition, the 
emWave’s “quick coherence technique” was reviewed and practiced during the first treatment 
visit. The technique involves attending to the physical area of the heart (“heart focus”), breathing 
deeply (“heart breathing”), and producing positive emotion (“heart feeling”). A more detailed 
description of these steps is listed in Appendix B. All treatment participants wore the Polar heart 
rate monitor during each entire biofeedback training session to allow for assessment of 
physiological change across training. Because individuals progressed in exhibiting adequate 
coherence levels at different paces, the length of training time was variable concerning total 
sessions completed. Guidelines provided by HeartMath in their Practitioner’s Guide (Culbert, 
Martin, & McCraty, 2007) suggest that four to six sessions are typically recommended, so a 
minimum for four completed sessions prior to completion of the post-test assessment was 
imposed. Sessions were 32 minutes in length, and they occurred approximately weekly. Days 
between the initial and follow-up visits ranged from 28 to 84 days. Control participants were 
yoked to treatment participants to assure equivalence of length of time between visits. 
 Participants practiced attaining increasing levels of moderate and/or high coherence as 
treatment progressed, thereby reducing the level of low coherence during sessions. Participants 
remained in treatment until they achieved < 50% low coherence (as suggested in the emWave 
practitioner’s guide) and evidenced a distinguishable peak within the low frequency range on the 
power spectrum within a training session. The latter criterion is not typically a part of emWave 
treatment. However, it was incorporated into the study protocol to assure that more typical HRV 
measures included in traditional HRV biofeedback were attended to by participants. Further, that 
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criterion should naturally be reached if coherence indeed is reflective of a peak around 0.1 Hz in 
the power spectrum, as noted earlier. Further, the above listed criteria had to be met first at the 
emWave’s low level of difficulty, and then again at the medium level of difficulty. If participants 
met those criteria within four sessions, they then completed the post-test session. For participants 
who did not meet these criteria by conclusion of the fourth session, they continued for up to four 
additional sessions before completing the post-test. 
Throughout treatment, participants were instructed to practice the techniques learned with 
the emWave program. They were instructed to do so for 10 minutes each day at a time when they 
were relatively calm and in an environment with as little distraction as possible. They also were 
instructed to practice the techniques when perceiving stress throughout the day. Participants were 
provided logs (see Appendix C) to record when they utilized the techniques and whether it 
occurred during a time of calm or of stress. The experimenter reviewed the logs with participants 
at each visit prior to beginning biofeedback so any questions or concerns the participants had 
could be addressed.  
3.5.3. Post-treatment Assessment. Following completion of the treatment sessions, the 
experimenter scheduled the final post-test session with participants. Visits for control group 
participants were yoked as closely as possible to visits for participants in the treatment group. 
Each time a treatment participant was scheduled for their post-test assessment, the experimenter 
scheduled a post-test assessment with the control participant who completed his or her initial 
assessment at the time closest to the corresponding treatment participant. The stressor protocol 
administered during the initial assessment was repeated. Using the quick coherence technique 
alters physiology and would obscure the physiological response normally expected during stress 
reactivity and recovery. Therefore, treatment participants were instructed not to use the 
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techniques learned during their biofeedback sessions. The writer monitored the heart rate 
waveform on the computer real-time during the assessment as well, as a distinct waveform is 
detectable when participants use the quick coherence technique, to detect whether participants 
were adhering to these instructions. Participants also were debriefed during the final session, and 
those in the control group were offered the opportunity to undergo biofeedback treatment. 
4. Results 
4.1. Data Reduction and Preparation for Analyses 
 4.1.1. Self-report Outcomes. Missing data for self-report outcome measures were 
extremely scarce in the current sample. Three participants omitted responses for between one and 
three items on the BSI. Following guidelines in the published BSI manual (Derogatis, 2001), 
calculation of scale scores was adjusted downward based on number of items with responses 
rather than absolute number of scale items. According to the manual, integrity is maintained with 
up to 25% of items missing. The largest proportion missing in the current sample among the 
three participants with missing data was 5.7%. Additionally, one participant failed to respond to 
one item on the PSS at the pre-test assessment. Mean imputation was utilized in this case. 
Otherwise, data were intact for BSI, PSS, and MAACL-R measures. 
 Skew and kurtosis were examined for BSI, PSS, and MAACL-R data. No abnormalities 
were present for PSS scores. Skew and/or kurtosis were significant (i.e., exceeding absolute 
value greater than 3 or 10, respectively) for the following scales at the pre- and/or post-test 
assessments: MAACL-R Positive Affect, MAACL-R Hostility, MAACL-R Sensation Seeking, 
BSI Anxiety, and BSI Phobic Anxiety. Therefore, data for both sessions and all task periods for 
these subscales were logarithmically transformed to promote normality of data. Following the 
transformation, skew and kurtosis were within acceptable limits with the exception of (1) the 
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Hostility subscale of the MAACL-R during the rest period at the pre-test session (skew = 4.32; 
kurtosis = 19.31) and (2) the Phobic Anxiety subscale of the BSI at the post-test session (skew = 
3.52, kurtosis = 14.06). Inspection of the data revealed that the elevation was due to two 
participants who endorsed at least one item on each scale; the remaining respondents endorsed 
no items on either scale. However, there was no indication of error in data entry or subject report 
on the measure. Rather, the data point seemed to genuinely reflect higher levels of self-reported 
hostile affect and phobic anxiety among outliers. To maintain the integrity of the data, the 
outliers were not removed.  
 4.1.2. Physiological Outcomes. Heart rate data for each period of pre- and post-treatment 
assessment sessions (i.e., Initial Rest Period; Mental Arithmetic Task; Mental Arithmetic 
Recovery; Handgrip Task; Handgrip Recovery) were collected using the Polar monitor and 
imported to Kubios HRV Analysis Software v2.0 (Biosignal Analysis and Medical Imaging 
Group, Kuopio, Finland) for preparation and analysis of HRV. Within the Kubios program, R-R 
interval data were visually inspected for aberrant or missing data. Low-level artifact correction 
was employed in these cases using the artifact correction feature of Kubios, which applies an 
interpolation method to correct erroneous data. In six instances, heart rate data were not 
transmitted effectively from the Polar monitor during one or two portions the stressor protocol, 
resulting in a gap in R-R interval data (e.g., 15 seconds during baseline).  These sections of data 
were removed due to clear invalidity, and analyses were performed both including and excluding 
these participants’ data. Findings did not differ meaningfully between analytical approaches, so 
data reported below include these participant’s data. 
 Following screening and error correction of the physiological data, LF and HF HRV 
values were logarithmically transformed. As frequency domain HRV data (i.e., LF HRV and HF 
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HRV) are known to suffer from skewness, implementing log transformation is a widely 
encouraged and implemented practice (e.g., Kuo et al., 1999; Pinna et al., 2007). 
4.2. Preliminary Analyses  
 Several analyses were deemed necessary prior to conducting primary study analyses, 
including: (a) examining demographic characteristics of the treatment and control groups to 
assure group equivalence on pertinent variables; (b) examining relations between HRV and 
potential covariates; (c) demonstrating that the tasks chosen to elicit stress responses evoked 
changes in measures of cardiovascular functioning; (d) determining whether the two stressor 
tasks chosen for this study elicited comparable cardiovascular and affective responses; (e) 
demonstrating that participants in the treatment group evidenced changes in coherence using the 
emWave biofeedback protocol; and (f) examining whether participants in the treatment group 
adhered to homework practice using the techniques taught in between training sessions.     
 4.2.1. Group Differences on Demographic Variables. Analyses were performed (i.e., t, 
χ2, or φ) to determine whether treatment and control groups differed regarding the demographic 
characteristics of sex, age, height, weight, BMI, race, ethnicity, parent income, and student status 
(i.e., graduate versus undergraduate). As depicted in Table 1, no significant differences were 
evident on any demographic characteristic (all ps > .05).   
 4.2.2. Potential Covariates. As sex, age, and BMI are often associated with heart rate 
and/or HRV (e.g., Bonnemeier et al., 2003; Felber Deitrich et al., 2006), correlational analyses 
were performed to examine the presence of significant relations between these three variables 
and HRV data to identify potential covariates for use in the primary study hypotheses. These 
analyses were conducted using Pearson’s correlation coefficients. As depicted in Table 2, age 
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was related to several measures of HRV and was therefore incorporated as a covariate in all main 
analyses involving physiological data. 
4.2.3. Evidence of Stress Reactivity to Tasks. To validate the two tasks chosen to assess 
participants’ stress responses in this study, heart rate level during each task was examined to 
confirm that heart rate increased significantly from the pre-task rest period to the task period. 
During mental arithmetic and handgrip tasks at both the pre- and post-test sessions, heart rate 
was significantly higher in comparison to the pre-task rest period from the same session (all ps < 
.001; see Table 3). 
 4.2.4. Task Differences. To determine whether significant differences existed in 
reactivity to the two stressor tasks, 2 (Group) X 2 (Task) ANCOVAs were performed using pre-
treatment HRV, covarying respective pre-task resting values. As depicted in Table 4, no Group 
X Task interactions were significant for any HRV measure (all ps > .05), nor were any main 
effects for Task significant (all ps > .05). Comparable analyses were conducted on HRV 
reactivity values at post-treatment with comparable results (see Table 4). Based upon these 
findings, HRV data were averaged across the two tasks at both pre- and post-treatment phases for 
conducting the primary study analyses.  
Analysis of task differences in affective responding revealed that while no significant 
task differences were noted for Anxiety, Depression, Hostility, and Positive Affect, there was a 
significant difference in Sensation Seeking between the math and handgrip tasks. Therefore, data 
for Sensation Seeking was analyzed separately for the two stressor tasks. Data for the remaining 
MAACL-R subscales (i.e., Anxiety, Depression, Hostility, Positive Affect) were aggregated 
across tasks. 
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 4.2.5. Heart Rate Variability and emWave performance during treatment sessions.  
Participants completed a minimum of four sessions, and a maximum of eight sessions. Sessions 
occurred approximately weekly. 
Prior to examining primary study hypotheses, it is important to demonstrate that 
participants in the treatment group actually acquired some skill at regulating their physiologies 
during training sessions.  Two types of data from treatment group participants were examined for 
this purpose: HRV data collected during biofeedback training sessions from the Polar monitor, 
and values from each training session based upon coherence information from the emWave 
program. The following point system was developed to determine how successful study 
participants were in completing emWave coherence training for each session: 
 
Point Type Criteria Point Value 
Session Difficulty 
Low Difficulty 1 
Medium Difficulty 2 
High Difficulty 3 
Very High Difficulty 4 
Coherence 
< 50 (of 100) coherence points in the low 
coherence category for each entire session 
1 
> 50% (of 100) coherence points in the low 
coherence category for each entire session 
0 
HRV Points 
Distinct peak was apparent in the LF range  1 
No distinct peak was apparent in the LF range  0 
 
Using this schema, the maximum point value earned for a single training session was six; 
four session difficulty points for engaging in training with very high difficulty, one coherence 
point for exhibiting more than 50% of data points in the high coherence range, and one HRV 
point for displaying a distinct peak in the LF frequency range. All participants completed four 
sessions, but some completed up to eight sessions because they did not meet the established 
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training criteria (i.e., < 50% data points in the low coherence range and a distinct peak in the LF 
range for both low and medium levels of difficulty) by the end of the fourth training session. For 
participants completing fewer than eight sessions, the final observed data point from the last 
completed session (e.g., Sessions 4 or 6) was carried forward for each participant through session 
8.  
 HRV values obtained from the Polar HR Monitor during training and point accumulation 
from the emWave protocol for treatment group participants were compared across training trials 
using repeated measures ANCOVAs. No changes in HRV across treatment sessions were 
apparent when analyzed in a variety of ways (e.g., examining changes across the first four 
sessions, between the first and last session, between the beginning and end of each or all 
sessions) (ps > .05). Table 5 contains relevant data for the comparison of HRV between the first 
and the final treatment session, illustrating the lack of change in HRV from the initiation to 
conclusion of treatment. Conversely, an increase in emWave performance points was apparent 
across sessions, F(1, 10) = 61.73, p < .001, wherein performance improved over time on average 
across participants (see Figure E2, Table 6). Post-hoc analyses revealed that sessions 1-3 differed 
from all other sessions (ps < .01), whereas sessions 4-8 did not differ significantly from each 
other (ps > .05), likely because data for participants completing fewer than 8 sessions were 
carried forward for these analyses. 
 4.2.6. Home Practice of Treatment. Thirteen of 14 treatment participants completed 
homework logs in between treatment sessions. One participant did not submit logs, but reported 
practicing the technique. For the remaining 13 participants, practice of the quick coherence 
technique reportedly occurred during both calm and stressful times during their daily lives. The 
average number of minutes practiced during times of calm and of stress per week was 44.29 (SD 
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= 24.48; range: 9-89) and 47.37 (SD = 37.13; range: 7-110) minutes, respectively. Overall, the 
average amount of homework practice was 98.46 (SD = 60.79 range: 17 - 197) minutes per 
week. The average number of emWave performance points earned during each session and the 
average number of minutes practiced per week were not significantly correlated (r = .19, p > 
.05). 
4.3. Primary Analyses 
 Mixed factors 2 (Group: Treatment, Control) x 2 (Session: Pre- vs. Post-treatment) 
analyses of covariance (ANCOVAs) were performed to test for differences in tonic HRV, phasic 
HRV reactivity to stress, and HRV recovery from stress before and after treatment. As 
mentioned above, age was used as a covariate for these analyses. Dependent variables included 
LF and HF HRV, as well as RMSSD, pNN50, and SDNN. To assess for differences in self-
reported affect from pre- to post-treatment, comparable 2 x 2 ANCOVAs were conducted, with 
BSI, PSS, and MAACL-R data serving as dependent variables. For analyses of reactivity, pre-
task rest period parameters were also included as covariates to control for potential differences in 
resting levels of the observed parameters. 
4.3.1. Physiological Outcomes 
 4.3.1.1. Tonic Measures of Heart Rate Variability. Results of the ANCOVAs on tonic 
measures of HRV measured from the initial rest period of the pre- and post-treatment assessment 
sessions revealed neither significant main effects for Session nor Group by Session interactions 
(see Table 7). This indicates that treatment using the emWave protocol did not influence tonic 
HRV in study participants. However, there were significant main effects for Group for both LF 
HRV and SDNN. At rest, the treatment group exhibited higher LF HRV (EMM = 7.20 logms
2
, SE 
= 0.21) and SDNN (EMM = 69.59 logms
2
, SE = 4.16) than the control group (LF HRV, EMM = 
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6.40 logms
2
, SE = 0.22; SDNN, EMM = 51.27 logms
2
, SE = 4.31). Despite randomized group 
assignment, participants in the treatment group evidenced higher levels of autonomic stability 
than control participants, a phenomenon that was evident both prior to and following the 
treatment phases. Based upon these findings, resting measures of HRV were incorporated as 
covariates in all subsequent analyses of HRV parameters. As such, results of subsequent analyses 
of task reactivity to stress and recovery from stress were not influenced by any group differences 
in resting physiology.  
 4.3.1.2. Phasic Heart Rate Variability Reactivity to Stress. Using aggregated reactivity 
data across both tasks (i.e., mental arithmetic and handgrip), Group X Session ANCOVAs were 
performed on LF HRV, HF HRV, SDNN, RMSSD, and pNN50 during the stressor tasks, 
covarying age and corresponding resting levels of HRV. A significant Group X Session 
interaction was evident for pNN50. The treatment and control groups did not differ regarding 
HRV reactivity to stress during the pre-treatment session, F (1, 23) = 0.60, p > .05, but showed 
significant group differences in pNN50 stress reactivity values at the post-treatment session, F 
(1, 23) = 6.25, p < .05, ηp
2 
= 0.21 (See Table 8 for ANCOVA Summary Table and Figure E3).  
Specifically, the treatment group exhibited higher pNN50 stress reactivity (EMM = 25.58 
percent, SE = 2.38) than the control group (EMM = 16.98 percent, SE = 2.47) at the post-test 
session. Adopting the .05 level of confidence, no significant main effects or interactions were 
observed for LF HRV, HF HRV, SDNN, or RMSSD reactivity (all ps > .05; see Table 8). 
 4.3.1.3. Heart Rate Variability Recovery from Stress. Analyses on all measures of HRV 
recovery following exposure to stressor tasks yielded no main effects or interactions for LF 
HRV, HF HRV, SDNN, RMSSD, and pNN50 recovery (ps > .05; see Table 10). 
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 4.3.1.4. Exploratory analyses of Treatment Responders. Two participants progressed 
less consistently and expeditiously than the other 12 participants in the treatment group, raising 
the possibility that their gains may have been different in quality or quantity than the remaining 
participants who engaged with the emWave treatment. The main analyses explained above were 
repeated excluding these two participants to explore whether their inclusion influenced study 
findings.  
 The interaction between Group and Session for pNN50 reactivity remained significant, 
and comparable interactions reached statistical significance in the exploratory analyses for LF 
HRV, SDNN, and RMSSD (see Table 9). Follow-up analyses evidenced that exclusively in the 
treatment group, LF (ηp
2 
= 0.58), SDNN (ηp
2 
= 0.50), pNN50 (ηp
2 
= 0.78), and RMSSD (ηp
2 
= 
0.61) were higher during stress during the post-treatment session relative to the pre-treatment 
session (ps < .05). The control group showed no significant changes in LF HRV, SDNN, pNN50 
or RMSSD in response to stress from pre- to post-treatment sessions (all ps > .05). The 
interaction for HF HRV was not significant. Finally, consistent with the main analyses including 
all study participants, there were no apparent treatment effects on HRV recovery following stress 
when conducting these  analyses using only treatment responders. 
4.3.2. Supplementary Self-report Measures 
 4.3.2.1. MAACL-R. As shown in Table 11, no significant Group X Session interactions 
were observed for measures of affective response to stress using the MAACL-R. This indicates 
that the emWave training did not influence affective response to the laboratory stressors used in 
this study. Several main effects for Session were detected, including Sensation Seeking during 
the mental arithmetic task, F(1, 24) = 6.44, p < .05, ηp
2 
= 0,21, and Depression, F(1, 24) = 7.82, p 
= .01, and Anxiety, ηp
2 
= 0.24, F(1, 24) = 4.61, p < .05, ηp
2 
= 0.16, during pre-task rest periods. 
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During the mental arithmetic task, all participants reported higher sensation seeking at the post-
treatment session (M = 0.63, SD = 0.79) compared to the pre-treatment session (M = 0.41, SD = 
0.84). Self-reported depressed and anxious affect decreased on average from pre-treatment 
(Depression: M = 0.78, SD = 1.19; Anxiety: M = 1.37, SD = 2.08) to the post-treatment 
assessment sessions (Depression: M = 0.37, SD = 0.84; Anxiety: M = 0.56, SD = 0.85). No main 
effects of Group were observed for any measure of affective responding.  
 4.3.2.2. Perceived Stress Scale. A 2 (Group) x 2 (Session) ANOVA on PSS scores 
revealed a significant main effect for Session, F(1, 24) = 6.23,  p < .05, d = 0.45 (see Table 11). 
Self-reported stress decreased from pre- (M = 38.87, SD = 7.87) to post-treatment (M = 35.37, 
SD = 7.52) assessment sessions for all study participants. Decreases in self-reported stress levels 
did not differ between treatment and control groups, however. 
 4.3.2.3. Brief Symptom Inventory.  All nine subscales of the BSI, as well as the Global 
Severity index, were analyzed using 2 (Group) x 2 (Session) ANOVAs (see Table 11). Main 
effects for Session were observed for the Global Severity Index, F(1, 25) = 5.51, p < .05, ηp
2 
= 
0.18, and the Anxiety, F(1, 25) = 5.44, p < .05, ηp
2 
= 0.17, and Somatization, F(1, 25) = 5.24, p < 
.05, ηp
2 
= 0.17, subscales; in all cases, reports of symptom-related distress decreased significantly 
between the pre- and post-treatment assessment sessions. A main effect for Group emerged for 
the Anxiety subscale as well, F(1, 25) = 4.28, p < .05, ηp
2 
= 0.15, wherein the treatment group 
reported higher levels of anxiety than the control group. No other main effects or interactions 
were significant for any remaining BSI measures.  
5. Discussion 
 The current study was designed to empirically address gaps in the HRV biofeedback 
literature, specifically pertaining to the delivery of HRV biofeedback using the emWave system. 
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Although it may be anticipated that improvement in HRV would be secondary to improvement in 
coherence through biofeedback training with the emWave, no studies to date have been designed 
expressly to examine this possibility. Prior investigation of the efficacy of biofeedback training 
via emWave exhibited conflicting findings regarding physiological effects and contained 
significant flaws in method, making it difficult to draw any firm conclusions. Therefore, one 
main aim of this study was to determine whether emWave treatment resulted in changes in tonic 
HRV. Another limitation of emWave, and the larger HRV, biofeedback literature is that little 
interest in examining the effects of training on phasic physiological responses to stress is evident. 
As HRV biofeedback may exert clinical improvements through improving the physiological 
response to stress, examining treatment effects on change in phasic physiological responses to 
stress is critical. Therefore, the other aims of the current study were to test whether emWave 
treatment conferred improvement in HRV reactivity during a stressor and in HRV recovery 
following stress. 
5.1. Effects of emWave Training on Physiological Measures 
 Linear, additive changes in HRV indices were not apparent across biofeedback training 
sessions in this study. Although acute increases in LF HRV during individual biofeedback 
sessions are apparent in traditional HRV biofeedback studies, evidence also suggests that 
cumulative and significant improvements in HRV across treatment visits in biofeedback sessions 
do not occur (Wheat & Larkin, 2010). In a recent study, coherence values based on participants’ 
performance during emWave biofeedback sessions were calculated to examine whether 
coherence changed across treatment sessions (Henriques, Keffer, Abrahamson, & Horst, 2011). 
According to the investigators, increases on coherence were expected to accompany the 
documented decreases in reported anxiety across time. Counter to the authors’ expectations, 
HRV Biofeedback      35  
however, improvement in coherence across 4 weeks of biofeedback sessions did not occur. This 
finding is consistent with the traditional HRV biofeedback literature in which clinical effects are 
frequently observed despite consistent and/or significant changes in underlying physiology. For 
example, Karavidas and coauthors (2007) utilized the traditional HRV biofeedback protocol with 
a depressed sample and found that improvements in depression at the fourth biofeedback session 
appeared to be coupled with improvements in HRV. However, improvements in HRV did not 
persist across future sessions, whereas improvements in depressive symptoms persisted.  
 In order to examine changes in physiology occurring during emWave training, a scoring 
rubric was developed for use in the current study to assess change and to dictate progression of 
each participant through treatment. Despite lack of observable change in traditional HRV 
measures (e.g., LF HRV, HF HRV, SDNN) during training, improvement in emWave coherence 
scores and LF power spectrum peaks were detected across biofeedback treatment sessions. This 
suggests that participants acquired skill over time in manipulating coherence as presented by the 
emWave training protocol, but that these changes were not paralleled by changes in HRV. 
 5.1.1. Tonic Heart Rate Variability. An effect of emWave treatment on tonic, or 
resting, levels of HRV was not apparent in any measure of HRV in our study. Participants 
receiving emWave treatment did not evidence significant change in resting LF, HF, SDNN, 
pNN50, or RMSSD measures of HRV from the pre-treatment to post-treatment periods. One 
previous emWave study examined changes in physiology following treatment and found that 
individuals receiving emWave treatment showed increases in the ratio of LF HRV to HF HRV 
(McCraty et al., 2003a), a somewhat controversial measure of sympathovagal balance (Berntson 
et al., 1997). However, this change was not contrasted against a control group so it is unclear 
whether this effect was due to treatment or some unrelated factor (e.g., time) (McCraty et al., 
HRV Biofeedback      36  
2003a). Also, no changes were noted in resting LF HRV, HF HRV, SDNN, or RMSSD in their 
study. Therefore, the current results largely replicate the finding that emWave treatment does not 
appear to change resting levels of HRV. The current study was designed explicitly to examine 
changes in resting HRV following emWave treatment. Therefore, no compelling evidence exists 
to date to support that tonic HRV is altered via emWave treatment. 
 The current results also are largely consistent with the traditional HRV biofeedback 
literature. Two traditional HRV biofeedback studies showed evidence of change in tonic SDNN 
or total HRV following HRV biofeedback treatment (Del Pozo et al., 2004; Zucker, Samuelson, 
Meunch, Greenberg, & Gevirtz, 2009), but suffered several methodological shortfalls. 
Conversely, several other studies with greater methodological rigor failed to document changes 
in tonic SDNN or total HRV (Karavidas et al., 2007; Lehrer et al., 2003; Lehrer et al., 2004; 
Swanson et al., 2009). One recent investigation of traditional HRV biofeedback documented 
changes in resting LF HRV (Hallman et al., 2011). However, this finding is not commonly 
observed, and the majority of studies have failed to find evidence for changes in resting or tonic 
LF HRV (Hassett et al., 2007; Karavidas et al., Lehrer et al., 2003; Lehrer et al., 2004). 
Differences in tonic HF HRV have not been found in any study using HRV biofeedback (Cowan 
et al., 2001; Hassett et al., 2007; Hallman et al., 2011; Karavidas et al., 2007; Lehrer et al., 
2003), and differences in tonic RMSSD and pNN50 have not been examined prior to the current 
investigation. Therefore, absence of change in tonic measures of HRV following training with 
emWave biofeedback in this study is congruent with the majority of studies using traditional 
HRV biofeedback and the limited research using the emWave protocol. Available evidence 
suggests that HRV biofeedback does not reliably confer changes in resting HRV. 
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 Absence of changes in tonic measures of HRV may be considered evidence against the 
effectiveness of HRV biofeedback in general and in emWave treatment specifically, but caution 
must be exercised in this interpretation. Although changes in tonic HRV would certainly be 
beneficial and lend credence to the efficacy of HRV biofeedback, such changes may not be 
needed in order to confer therapeutic clinical advantages. For example, change in HRV (phasic 
HRV) in response to internal or environmental stressors may represent a more important 
outcome associated with biofeedback interventions than any potential change in tonic level of 
HRV. Therefore, improved phasic HRV in the context of stress may be more relevant and 
compelling than changes in tonic HRV. 
 5.1.2. Phasic Heart Rate Variability. Evidence was limited in the current study for 
changes in phasic HRV following emWave treatment. Neither the control nor treatment group 
showed evidence of change in LF HRV, HF HRV, SDNN, or RMSSD during stress. However, 
the treatment group exhibited higher pNN50 during stress relative to the control group at the 
post-treatment session. As pNN50 is largely indicative of parasympathetic function (Task Force, 
1996), this effect suggests that emWave treatment resulted in increased parasympathetic 
augmentation, or less parasympathetic withdrawal, in response to stress.  
 The current study is one of two studies that have assessed phasic changes during stress in 
HRV following emWave treatment, and is only one of three to assess such changes within the 
HRV biofeedback literature as a whole. Another study utilized the Freeze-Frame (prior version 
of emWave) with children in middle school and found no changes in reactivity to stress 
(McCraty et al., 1999). HF and LF HRV were examined, but pNN50 was not measured. 
Therefore, the current finding showing changes in pNN50 reactivity to stress among treatment 
participants cannot be compared to McCraty et al.’s findings directly. Further, interpretation of 
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their results is extremely difficult for several reasons. For example, HRV biofeedback was part 
of a larger intervention with several other components that may have influenced HRV outcomes, 
and not all participants received biofeedback as part of the overall treatment.  
 The only other study offering results for comparison found that participants receiving 
traditional HRV biofeedback showed increases in pNN50 (hand grip and cold pressor tasks) and 
LF HRV (hand grip task only) during stress between pre- and post-treatment periods, while the 
control group did not show increases across time points (Hallman et al., 2011). Therefore, 
although evidence is limited, the current study and previous findings from Hallman et al. (2011) 
suggest that HRV biofeedback confers increases in parasympathetic activation in the context of 
stress. It is possible, then, that HRV biofeedback might effectuate physiological mitigation of the 
stress response by supporting parasympathetic activity to buffer a strong sympathetic reaction to 
stress.  
 Although Hallman and colleagues (2011) also found increases in LF HRV during a hand 
grip stressor, this finding was not replicated with the cold pressor task in their study, and current 
results using all study participants did not indicate a change in LF HRV during phasic responses 
to stress. Phasic changes during stress in LF HRV therefore are not consistently observed. Of 
note, neither the current results nor those of Hallman and coauthors (2011) showed significant 
changes in HF HRV or SDNN in reaction to stress. Therefore, changes in parasympathetic 
activity during stress appears to be susceptible to change following HRV biofeedback treatment, 
but parallel changes in other HRV parameters appears less likely based on available data. 
 It should be noted that exploratory analyses of treatment responders in the current study 
indicated that effects of emWave biofeedback on HRV reactivity may extend beyond the single 
measure of pNN50. When the two participants who appeared to respond to treatment differently 
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than other treatment participants were excluded and main analyses of physiological outcomes 
were repeated, significant Group by Session interactions emerged for LF HRV, SDNN, and 
RMSSD during stress. This pattern of results would indicate a more general increase in HRV 
during stress following emWave intervention, as opposed to an isolated effect on 
parasympathetic nervous system functioning (i.e., pNN50). No established parameters exist to 
differentiate treatment responders from non-responders per se, so excluding these two 
participants could introduce selection bias into the research design. The two participants may 
represent a subset of individuals whose phasic physiology does not respond to emWave 
treatment, whereas the majority of participants who received emWave training represented a 
group that did experience changes in phasic physiology following treatment. This will be an 
avenue for future studies to pursue. Another possibility is that these participants experienced 
frustration due to difficulty in improving consistently across sessions, which may have affected 
their physiological presentation at the post-test assessment. As they engaged in more sessions 
than the other treatment group members, these two participants also had a longer time period 
between the pre- and post-test assessment visits. However, this is unlikely to have affected the 
outcome, as control group participants’ assessment visits were yoked with visits of participants 
in the treatment group on length of time since the initial session. 
 5.1.3. Heart Rate Variability Recovery. Whereas results of the current study support a 
treatment effect of the emWave on pNN50 during stress, there were no effects of treatment on 
recovery from stress for pNN50, or any other HRV parameter. Therefore, results of the present 
study do not support the efficacy of emWave treatment in improving physiological restoration of 
the autonomic nervous system’s tonic levels of activity. In their study of implementing HRV 
biofeedback and other self-regulation treatments in middle schoolers, McCraty and associates 
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(1999) found improvements in LF HRV during recovery from stress. As noted above, however, 
interpretation of the results of this study is difficult due to flaws in study design. Ultimately, no 
reliable data exists to date indicating efficacy of emWave treatment in improving HRV recovery 
from stress. 
 Two traditional HRV biofeedback studies assessed changes in HRV during recovery 
from stress. One study reported significant increases in HF HRV between periods of stress and 
recovery during a physical stressor task (Nolan et al., 2005). However, they did not report 
controlling for resting levels of HRV. Therefore, evidence from this study of improvement in HF 
HRV during recovery is weak. The results of Hallman et al.’s (2011) study showed increases 
from pre- to post-treatment for the treatment group in SDNN during recovery from a hand grip 
stressor, and no changes emerged for the control group. No improvements in SDNN during 
recovery from the cold pressor task were observed, and improvements were lacking in all other 
HRV outcomes assessed for recovery from the handgrip and cold pressor stress tasks (i.e., HF 
HRV, LF HRV, and pNN50). 
 The current study is the first investigation designed to examine the efficacy of the 
emWave as a standalone treatment in facilitating improvement in phasic physiological responses 
to stress. Partial support for its efficacy was garnered in that there was evidence for a treatment 
effect on parasympathetic responses to stress as measured by pNN50. This finding aligns with 
outcomes for pNN50 during stress reported in a traditional HRV biofeedback study (Hallman et 
al., 2011). Therefore, change in parasympathetic activity during stress following HRV 
biofeedback treatment appears plausible. However, the strength and reliability of this effect is 
questionable in light of non-significant findings for the other measures of parasympathetic 
activity (i.e., HF HRV and RMSSD) in this study, and for HF HRV in Hallman et al.’s (2011) 
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investigation. If HRV biofeedback conferred a strong and reliable effect on parasympathetic 
function during stress, change across other indices of parasympathetic function may be expected; 
however, this has not been borne out consistently in the existing studies. Selection bias aside, the 
current study does provide some preliminary data supporting a broader increase in multiple HRV 
measures in response to emWave training among participants who responded to the intervention.  
 Although changes during the stress response itself may be important in this buffering 
process, recovery from stress is a critical process as well because extended periods of arousal and 
related failure to return to physiological homeostasis can also burden the cardiovascular system. 
Whereas some support was found for changes in stress reactivity following emWave treatment, 
no evidence was observed in the current study for efficacy of emWave treatment in altering HRV 
during recovery from stress. Those receiving emWave treatment did not differ from those in the 
control group in HRV outcomes following stress after completing treatment. Considering the 
current results within the context of the few existing investigations of changes in recovery from 
stress following HRV biofeedback treatment, there is little evidence for treatment effects, and 
inconsistencies are lacking in what little support is available. Therefore, current evidence does 
not indicate that reliable change in physiological recovery from stress occurs following HRV 
biofeedback treatment. 
  Although previous literature examining physiological effects of emWave is limited in 
number of studies and is wrought with methodological flaws, the traditional HRV biofeedback 
literature also shows little evidence for long-term changes in HRV as a result of HRV 
biofeedback treatment. Several of these studies using traditional HRV biofeedback evidence 
acute changes in LF HRV, as would be expected, during biofeedback practice (see Wheat & 
Larkin, 2010). However, lasting physiological changes in tonic HRV generally are not supported 
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by current evidence. This study, and results of other studies examining the effects of the 
emWave, are therefore consistent with the HRV biofeedback literature at large, in that treatment 
effects on resting HRV are not apparent.  
 Despite the conception that improvements in HRV may serve to buffer the effects of 
stress on the cardiovascular system, very little research examining changes in phasic 
physiological responses to stress existed prior to this study. Further, the only study specifically 
examining phasic responses following emWave treatment (McCraty et al., 1999) was poorly 
designed to address that question. The current results add to the small body of literature on 
phasic responses to stress, indicating possible isolated improvements during stress in 
parasympathetic responding (i.e., pNN50), and no apparent improvements in recovery from 
stress. Considering the current results with the pre-existing evidence on changes in phasic 
responses, the lack of reliable or robust changes in tonic and phasic HRV following HRV 
biofeedback treatment is striking.   
 Although anticipating such changes is plausible given the conception that HRV 
biofeedback may confer clinical improvements in stress-related illnesses and symptoms by 
altering the stress response, it is possible that HRV biofeedback treatment exhibits clinical 
efficacy via another mechanism. For example, biofeedback practice may produce physiological 
effects other than changes in HRV, such as changes in inflammatory processes, which could 
facilitate improvement in clinical outcomes (Lehrer et al., 2004). Further, some literature 
supports changes in baroreflex function as a consequence of HRV biofeedback treatment (Lehrer 
et al., 2003; Lehrer at el., 2004), or baroreflex biofeedback (Reyes del Paso & Gonzalez, 2004). 
Baroreflexes also are thought to confer resonant properties on the cardiovascular system and to 
be exercised during traditional HRV biofeedback (Lehrer, 2007; Vaschillo, Vaschillo, & Lehrer, 
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2006). Given the parallels discussed earlier in this manuscript between biofeedback of the 
emWave and traditional biofeedback, it is possible that emWave biofeedback exercises the 
baroreflexes as well. Baroreflex function was not measured directly in the current study, so it is 
unknown currently whether emWave treatment exercises the baroreflexes and/or strengthens the 
baroreflex response to stress. However, given that no change in any measure of HRV was 
detected during emWave treatment sessions, and yet, participants exhibited increased pNN50 
during post-treatment stress exposures, it is possible that baroreflexes were being stimulated and 
exercised during treatment sessions.  Consequently, participants who exercised their baroreflexes 
during training displayed their improved baroreceptor “fitness” following treatments, but only 
when such reflex action was warranted (i.e., during stress). Therefore, the physiological effects 
of HRV biofeedback on adaptability of the physiological system to stress may be apparent in 
baroreflex improvement, rather than in changes in the HRV parameters included in the current 
investigation. 
5.2. Effects of emWave on Affective Responses to Stress 
 State affect in the context of stress was assessed to supplement measures of physiological 
indices of reactivity and recovery. No significant interactions emerged for any of the MAACL-R 
subscales. Therefore, there were no apparent treatment effects of the emWave training protocol 
on affective responses to stress. Emotion regulation is part of the quick coherence technique 
utilized during the biofeedback sessions by treatment participants. However, participants were 
instructed not to use any of these methods during the post-treatment assessment as doing so 
would influence HRV and make discernment of treatment effects on phasic physiological 
responding impossible. Therefore, emotion regulation strategies utilized during biofeedback 
sessions should not have translated to the post-treatment session and been apparent in MAACL-
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R responses. None of the emWave or traditional HRV biofeedback studies implementing stressor 
protocols assessed affective responses as part of the stressor protocols, so comparisons to 
previous investigations were not possible. 
5.3. Effects of emWave on Stress and Psychological Symptom Distress 
 Most studies examining the effects of emWave treatment focused on non-physiological 
outcomes. Therefore, self-report measures of general stress and distress secondary to 
psychological symptoms were included for purposes of supplementing physiological outcome 
indices. 
 No interactions emerged for scores on the BSI or any subscales of the PSS to demonstrate 
that emWave treatment affected psychological symptom distress or overall self-reported stress 
levels. The main effects of session (i.e., the Global Severity Index of the BSI, the Anxiety and 
Somatization subscales of the BSI, and PSS scores reduced across sessions in both groups) may 
reflect regression toward the mean. Due to the absence of an interaction between group and 
session, these observed reductions within the treatment group cannot be attributed to emWave 
treatment effects. 
 Several investigations of effects of emWave (or Freeze-Framer) treatment on stress and 
mental health outcomes have been conducted (e.g., Barrios-Choplin et al., 1999; Climov, 2008; 
McCraty, Atkinson, Lipsenthal, & Arguelles, 2003; McCraty et al., 2003b; McCraty, Atkinson, 
Tomasino, Goelitz, & Mayrovitz, 1999; McCraty, Tomasino, Atkinson, Aasen, & Thurik, 2000). 
Each of these studies evidenced some change, if not several changes, in psychological 
parameters from pre- to post-treatment, and changes were in anticipated directions (i.e., 
reductions in symptom levels). Unfortunately, aspects of the studies were often too poorly 
planned or controlled (e.g., lack of control group, inconsistent application of biofeedback across 
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participants, development of a measure without appropriate of validity/reliability assessment) to 
make meaningful conclusions regarding these changes viable. Further, the findings tended to be 
inconsistent across studies when the same measures were used across multiple investigations.  
 Several peer-reviewed studies on the effects of HRV biofeedback training included self-
report measurement of related constructs. One of these studies utilized emWave treatment, and 
decreases were evident across groups in anxiety and general distress as measured by the State-
Trait Anxiety Inventory and the Mood and Anxiety Symptom Questionnaire (Henriques et al., 
2011). However, there were no interaction effects to demonstrate a treatment effect specific to 
the emWave treatment protocol. Several traditional HRV biofeedback studies have also provided 
evidence for decreases in reports of anxiety (Hospital Anxiety and Depression Scale) and/or 
depression (Beck Depression Inventory II; Hamilton Rating Scale for Depression; Hospital and 
Anxiety Depression Scale), but did not include a control group to allow the conclusion that these 
reductions were due to treatment effects (e.g., Giardino, Chan, & Borson, 2004; Hassett et al., 
2007; Karavidas et al., 2007). Other studies including control groups also found main effects for 
time or session across groups on reports of depression (Center for Epidemiologic Studies 
Depression Scale), stress (PSS), and/or positive and negative affect (Positive and Negative 
Affect Schedule), while failing to find interaction effects that would suggest a HRV biofeedback 
treatment effect (Nolan et al., 2005; Swanson et al., 2009). One study examining traditional HRV 
biofeedback reported a significant interaction between group and time wherein reports of 
depression were decreased to a higher degree in treatment participants than in control 
participants (Zucker et al., 2009). 
 In general, current results do not provide much evidence that emWave treatment reduces 
reports of stress or psychological distress across various domains (e.g., depression, anxiety), 
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which is consistent with the majority of findings of other HRV biofeedback studies. Further, the 
main effects for time across both groups on PSS and some BSI subscales appears to be consistent 
with prior literature showing similar patterns of main effects, without a differential effect of 
treatment on these outcomes. 
5.4. Study Limitations 
 Like all intervention research, this study is not without limitations. The emWave program 
was not designed for use in clinical trials and does not have an established protocol. Although 
those who developed the emWave program provided a clinician guide offering some 
recommended parameters for treatment delivery (Culbert et al., 2007), no evidence-based 
information regarding implementation of the emWave treatment is available to guarantee 
appropriate length of treatment, method for documenting progression in treatment, the necessary 
components to include in treatment, etc. Parameters for the current study were established based 
to some extent on clinical guidelines provided with the emWave clinician guide (e.g., minimum 
of 4 sessions). Other details were implemented to promote standardization across participants at 
the discretion of the author in the absence of empirical indication regarding standards of practice. 
It is possible that analyses for the current study did not reveal significant effects because the 
method of treatment delivery utilized for this study did not establish a sufficiently strong 
treatment effect. However, given that specific instructions for implementing training were not 
available, the protocol employed was at least congruent with recommended training procedures. 
It is possible, however, that training that lasted longer or employed a higher criterion for 
completion may have resulted in differential effects.  
 It also is possible that changes in tonic or phasic LF HRV, HF HRV, SDNN, pNN50, and 
RMSSD do not measure the mechanism through which HRV biofeedback exerts its clinical 
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effect. Changes in these parameters have not been commonly revealed in traditional HRV 
biofeedback studies.  Although the current study is among the initial empirical efforts to 
determine the effect of emWave treatment on tonic and phasic measures of HRV, the null 
findings are consistent with previous empirical work employing standard HRV biofeedback 
protocols. Improvements in baroreflex functioning may be a viable mechanism through which 
HRV biofeedback confers clinical improvement across medical and psychological symptoms 
(see Wheat & Larkin, 2010). As baroreflex functioning was not measured in the current study, an 
additional limitation of this investigation is that the effect of emWave treatment on this 
parameter cannot be explored. No other emWave study has measured baroreflex sensitivity or 
gain, so the ways in which their activity may be improved by emWave treatment cannot be 
determined at this time. 
 As the primary aim of this study was to examine physiological changes in response to 
emWave treatment, healthy volunteers were recruited for participation to eliminate potentially 
confounding disease states and interference by medications less health participants may have 
been prescribed. In this regard, the magnitude of treatment effects may have been negligible due 
to a ceiling effect, whereby participants already tended to exhibit adequate physiological 
responses to stress. A stronger likelihood of altering one’s physiological responses to stress may 
be observed among clinical samples where HRV and associated parameters are known to be 
compromised. Future research will be needed to evaluate the utility of altering one’s 
physiological responses to stress via HRV biofeedback among patients with chronic medical or 
psychiatric conditions. 
 The current study was the first to assess affective reactivity during a stressor protocol 
following emWave treatment. The MAACL-R was utilized for this purpose, and internal 
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consistency was low for some subscales of this instrument. In general, internal consistency of 
these scales has been established in other studies. The small sample size and low variance in 
affective responding among participants in the current study likely contributed to the poorer 
levels of internal consistency observed. Therefore, effect of emWave treatment on affective 
responses to stress could not be assessed with complete confidence. 
 An additional limitation of this study is that respiration was not measured concurrent to 
either assessment or training sessions and may have accounted for the relative lack of significant 
findings associated with biofeedback treatment. Courtney et al. (2011) illustrated that some 
individuals may exhibit dysfunctional breathing patterns that could affect their ability to improve 
HRV and obtain coherence during biofeedback. Individuals with these types of irregular 
breathing patterns may undergo treatment, but fail to optimize effects on HRV or exercise 
baroreflexes in the process. Therefore, if treatment effects are mediated by physiological changes 
that occur during biofeedback, the breathing abnormalities of these individuals could obscure 
treatment outcomes. As breathing patterns were not measured in this study, determining whether 
breathing dysfunctions existed among study participants was not determined, which may have 
affected results. For example, it is possible that the two participants excluded for the purposes of 
exploratory analyses showed these breathing abnormalities. The full analyses may have been 
tempered by inclusion of their data, thereby yielding largely non-significant results.  
 Further, participants were instructed to engage in utilizing the quick coherence technique 
independently, without the aid of biofeedback, each day between session visits. Although they 
logged practice, participants’ reports of practice may have been inaccurate or exaggerated, and 
practice may not have been physiologically adequate without the presence of biofeedback. As 
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these factors may have contributed to the low level of treatment effects noted, this also is a 
relative weakness of the current study. 
 Finally, a few aspects of the current study limit the generalizability of findings. First, our 
sample did not exhibit an even gender distribution. Although previous HRV biofeedback studies 
have not shown that males and females respond differently to relevant interventions, results of 
this study cannot be generalized to males due to their limited presence in this sample. Our 
sample may also be unique in that the participants were recruited from psychology courses 
and/or programs of study. Participants may have had more familiarity than individuals not 
formally educated in psychology with behavioral interventions for psychiatric and/or medical 
symptoms or illnesses, and it is possible that they may have been more amenable to engaging 
readily in emWave treatment for that reason. Additional evidence for the unique attributes of the 
study sample pertain to the finding that several HRV parameters, particularly those occurring 
during stress presentations, were positively correlated with participant age.  This suggests that 
the older participants who were graduate students in psychology had greater HRV, indicating a 
somewhat healthier stress response than the younger undergraduate participants. Given the 
number of years graduate students have studied the science of psychology, they may have had a 
greater opportunity to use their knowledge to develop more effective stress management skills 
than undergraduate students.  Alternatively, because the experimenter of the current study was a 
graduate student in psychology, graduate student participants may have simply been less stressed 
while engaging in the tasks for a peer than undergraduates performing for someone who they 
perceive as an authority figure. Regardless of the reason for this finding, age was covaried in all 
analyses to remove any variance accounted for by participant age.  
 
HRV Biofeedback      50  
5.5. Future Directions 
 Due to the paucity of peer-reviewed literature on effects of emWave treatment, there are 
several areas in which the literature may be improved. Within the context of HRV biofeedback in 
general, the current study also provides information for areas of improvement in that broader 
literature as well. 
 As noted above, although the current study examined the effects of emWave in healthy 
adults, examining the efficacy of emWave biofeedback in clinical populations in one avenue for 
future studies to address. It will be informative to extend the use of emWave in clinical 
populations to determine whether it may prove to be efficacious in producing physiological 
and/or clinical changes in those with psychiatric or medical complaints, as well as in those who 
exhibit affected physiology due to related conditions. An additional population that may benefit 
from emWave treatment is individuals involved in athletics. Prior investigations illustrate the 
utility of HRV biofeedback in improving performance in various athletic groups (e.g., Lagos, 
Vaschillo, Vaschillo, Lehrer, Bates, & Pandina, 2011; Raymond, Sajid, Parkinson, & Gruzelier, 
2005; Strack, 2003; Vaschillo, Vysochin, & Rishe, 1998). It is possible that the emotional and 
physiological regulation targeted by emWave treatment could improve attention, reaction time, 
performance, etc., in athletes in an accessible, affordable, and easily implemented format. Future 
studies may target athletes a special population in which to test the efficacy of the emWave. 
 This is the second HRV biofeedback study, and the first utilizing the emWave, that found 
an effect of treatment on pNN50 during reactivity to stress (Hallman et al., 2011). As this effect 
on parasympathetic responding during stress has been noted across a healthy sample (current 
study) and a sample of participants with pain (Hallman et al., 2011), as well as across two 
different modalities of HRV biofeedback, it may represent a reliable treatment effect. Replication 
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of this finding would be beneficial to determine if comparable effects can be noted across 
additional populations to which HRV biofeedback treatment is delivered. This is one promising 
avenue through which emWave treatment, or HRV biofeedback treatment in general, may confer 
a change in the physiological stress response. Investigators may also consider examining in a 
larger-scale study whether changes also occur in other HRV parameters, as exploratory analyses 
excluding two treatment participants evidenced a broader spectrum of changes in phasic HRV 
responses (i.e., pNN50 in addition to LF HRV, SDNN, and RMSSD). Our exploratory approach 
suggests that emWave intervention may confer general increases in HRV during stress, but this 
cannot be concluded with certainty at the current time.  
 Based on the larger biofeedback literature, baroreflex function may be a good candidate 
to consider when searching for the mechanism through with HRV biofeedback has exerted an 
influence on clinical outcomes. No emWave studies have implemented measurement of 
baroreceptor or baroreflex function, and a limited number of traditional HRV biofeedback 
studies have done so. In light of unreliable or non-existent chronic changes in measures of HRV 
(excepting the findings on pNN50 reactivity change with emWave noted above), increasing 
attention to baroreflex measures in subsequent investigations may help elucidate the mechanism 
involved in producing clinical changes following HRV biofeedback. 
 Ultimately, to rigorously assess the efficacy and effectiveness of emWave treatment as a 
viable way to treat emotional and physical disorders, a standardized treatment approach should 
be developed for use in empirical assessments of the treatment. A stage model for behavioral 
interventions (Rounsaville, Carroll, & Onken, 2001) offers guidelines on systematic efforts to 
build toward clinical trials that may establish empirically supported treatments. This study 
represents an effort to contribute to the first stage of those efforts, but much more empirical work 
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is necessary to progress beyond early stages toward full-fledged clinical trials. For example, 
investigations addressing treatment development, manual development, specification of session 
content, determination of treatment length, etc. will assist in maximizing the potential for 
efficacy of treatment and, importantly, testability of emWave treatment as such. 
 In a related vein, efforts should be made to evaluate components of emWave treatment in 
peer-reviewed arenas systematically. One recent study (Henriques et al., 2011) is a commendable 
example of subjecting the emWave treatment protocol to the same rigorous standards of 
empirical examination that have been applied to traditional HRV biofeedback treatment. Much 
investigation of emWave treatment (and its predecessor, Freeze-Frame) has been unsystematic 
(e.g., lack of control group, failure to adequately define treatment components, unequal delivery 
of treatment across participants), and some studies have not undergone the peer review process. 
Systematic development and investigation by third party researchers are warranted to truly 
determine the potential of emWave treatment as an efficacious approach to managing psychiatric 
or medical symptoms. 
6. Conclusions 
 Given the ease of use and relatively low cost of the emWave, continuing to investigate its 
effects to establish whether it reliably produces either physiological or clinical change is 
warranted.  The current study documented one way in which emWave treatment affected a 
limited aspect of phasic HRV responses to stress and, in doing so, replicated one other study 
finding a similar effect. Based on the understanding that HRV biofeedback may confer clinical 
improvements in disease states as documented in the literature, it is somewhat surprising that a 
bigger impact on physiology was not achieved in the current study. However, this appears to be 
an issue present in the traditional HRV biofeedback literature at large as well. The scientific and 
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clinical communities will benefit from broadening our conceptualization of ways in which HRV 
biofeedback may confer meaningful clinical changes and, in turn, move us forward to establish 
which modalities address this mechanism most efficiently and which populations may benefit to 
the greatest degree. 
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Appendix A 
Your age _____ 
Your sex 
 ○ Male 
 ○ Women 
Your race 
 ○ Black 
 ○ White 
 ○ Hispanic 
 ○ Native American 
 ○ Asian 
 ○ Biracial (specify):_______________ 
 ○ Other ________________________ 
Total years of education you have completed: 
 ○  High school 
 ○  1 year college 
 ○  2 years college 
 ○  3 years college 
 ○  4 or more years college 
Please describe any cardiovascular related illness that you may have, including high blood 
pressure:______________________________________________________________________
_____________________________________________________________________________. 
 
Please list any other medical or psychiatric problems that you have:_____________________ 
______________________________________________________________________________
_____________________________________________________________________________. 
Please list any major surgeries and medical, or psychiatric illnesses you have had in the past. 
______________________________________________________________________________
_____________________________________________________________________________. 
Females: When did you start your last menstrual cycle?  
 ○ I am a Male 
 ○ less than one week ago 
 ○ one week ago 
 ○ two weeks ago 
 ○ three weeks ago 
 ○ four weeks ago 
 ○ more than four weeks ago 
 ○ I am currently pregnant 
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Females: Are you currently on birth control (contraceptives). 
 ○ I am a male 
 ○ No 
 ○ Yes 
 
What type of birth control are you taking?  ___________________________ 
Please list any drugs (legal or otherwise) that you are currently taking including; birth control 
(contraceptives), heart medications, cold or allergy medications, over the counter medications, 
asthma medications, Beta-Blockers (i.e. Inderal, Tenormin), psychoactive drugs (i.e. Adderall, 
Xanax, Haldol, Lithium, Prozac), or diet pills. 
______________________________________________________________________________ 
______________________________________________________________________________
_____________________________________________________________________________. 
On average, how often do you smoke cigarettes? 
 ○ never 
 ○ I am not currently smoking 
 ○ less than one pack per day 
 ○ 1-2 packs per day 
 ○ 2-3 packs per day 
 ○ greater than 3 packs per day 
On average, how often do you use smokeless tobacco? 
 ○ never 
 ○ I am not currently using smokeless tobacco 
 ○ 1-4 times per day 
 ○ 5-8 times per day 
 ○ 9-13 times per day 
 ○ greater than thirteen times per day 
How often do you drink alcohol? 
 ○ never 
 ○ infrequently (a few drinks per year) 
 ○ occasionally (1-2 drinks per month) 
 ○ weekly (1-3 drinks per week) 
 ○ weekly (4-7 drinks per week) 
 ○ daily (7-14 drinks per week) 
 ○ daily (more than 14 drinks per week) 
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How many cups of caffeinated coffee, tea, or soda do you have per day? 
 ○ none 
 ○ 1-2 cups per day 
 ○ 3-4 cups per day 
 ○ 5-6 cups per day 
 ○ 7-8 cups per day 
 ○ greater than eight cups per day 
How many times per week do you engage in aerobic physical activity? 
 ○ never 
 ○ 1-2 times 
 ○ 3-6 times 
 ○ 7 or more times 
For how long do you typically exercise on each occasion? 
 ○ 5-10 minutes 
 ○ 11-15 minutes 
 ○ 16-30 minutes 
 ○ 31-60 minutes 
 ○ 61-90 minutes 
 ○ more than 90 minutes 
How many hours of sleep did you get last night? 
 ○ Less than 4 hours 
 ○ 4-5 hours 
 ○ 5-6 hours 
 ○ 6-7 hours 
 ○ 7-8 hours  
 ○ 8-9 hours 
 ○ greater than 9 hours 
 
Family Information: 
What is your best estimate of your family’s total income? 
 ○ Less than 24,999 
 ○ 25,000 to 34,999 
 ○ 35,000 to 49,999 
 ○ 50,000 to 74,999 
 ○ 75,000 to 99,999 
 ○ 100,000 to 149,999 
 ○ Greater than 150,000 
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How difficult was it for your parents to make their bill payments when you were young? 
 ○ Not difficult at all 
 ○ Somewhat difficult (missed a few payments, but rarely) 
 ○ Very difficult (often missed payments) 
 ○ Extremely difficult (could rarely make all their payments and had to choose what bills 
to   pay week-to-week) 
 
Approximately how old is your biological father? _________ 
If you are adopted, mark here _____ and report on your biological father or move to the section 
on your mother’s health 
 
What is your father’s highest level of education 
 ○ Some High School 
 ○ Graduated High School 
 ○ Some College 
 ○ Graduated College 
 ○ Some Graduate School 
 ○ Obtained Masters Degree 
 ○ Obtained Doctoral Degree 
What is your father’s occupation? _____________________________________________ 
Is he currently living? 
 ○ yes 
 ○ no 
Did/does your father have high blood pressure (hypertension)? 
 ○ yes 
 ○ no 
How certain are you that he did, or did not, have high blood pressure (hypertension)? 
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your father have any heart problems such as angina (chest pains), a heart attack, or 
coronary heart disease? 
 ○ yes 
 ○ no 
If yes, please specify if you are able: ______________________________________________. 
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How certain are you that he did, or did not, have a heart problem as indicated above?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your father have diabetes? 
 ○ yes 
 ○ no 
How certain are you that he did, or did not, have diabetes?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your father have a kidney disease (other than kidney stones)? 
 ○ yes 
 ○ no 
How certain are you that he did, or did not, have a kidney disease (other than kidney stones)?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your father have cancer? 
 ○ yes 
 ○ no 
How certain are you that he did, or did not, have cancer?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
If you know, please list what type(s) of cancer he had._____________________________ 
__________________________________________________________________________. 
 
Approximately how old is your biological mother? _________ 
 
If you are adopted, mark here _____ and report on your biological mother  
 
 
 
 
 
HRV Biofeedback      70  
What is your mother’s highest level of education 
 ○ Some High School 
 ○ Graduated High School 
 ○ Some College 
 ○ Graduated College 
 ○ Some Graduate School 
 ○ Obtained Masters Degree 
 ○ Obtained Doctoral Degree 
What is your mother’s occupation? _____________________________________________ 
Is she currently living? 
 ○ yes 
 ○ no 
Did/does your mother have high blood pressure (hypertension)? 
 ○ yes 
 ○ no 
How certain are you that she did, or did not, have high blood pressure (hypertension)? 
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your mother have any heart problems such as angina (chest pains), a heart attack, or 
coronary heart disease? 
 ○ yes 
 ○ no 
If yes, please specify if you are able: ______________________________________________. 
How certain are you that she did, or did not, have a heart problem as indicated above?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your mother have diabetes? 
 ○ yes 
 ○ no 
How certain are you that she did, or did not, have diabetes?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
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Did/does your mother have a kidney disease (other than kidney stones)? 
 ○ yes 
 ○ no 
How certain are you that she did, or did not, have a kidney disease (other than kidney stones)?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
Did/does your mother have cancer? 
 ○ yes 
 ○ no 
How certain are you that she did, or did not, have cancer?  
 ○ Absolutely (100%) certain 
 ○ Almost (75%) certain 
 ○ Not sure at all (25%) 
 ○ No information by which to judge (0%) 
If you know, please list what type(s) of cancer she had? _____________________________ 
__________________________________________________________________________. 
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Appendix B 
 The Quick Coherence Technique helps you create a coherent state, offering access to 
your heart’s intelligence. It uses the power of your heart to balance thoughts and emotion, 
helping you to achieve a neutral, poised state for clear thinking. It is a powerful technique that 
connects you with your energetic heart zone t help you release stress, balance your emotions, and 
feel better fast.  
 Quick coherence will help you find a feeling of ease and inner harmony that will be 
reflected in your heart rhythms. The heart is a primary generator of rhythm in your body, 
influencing brain processes that control your nervous system, cognitive function and emotion. 
More coherent heart rhythms facilitate brain function, allowing you more access to your higher 
intelligence so you can improve your focus, creativity, intuition and higher-level decision-
making. When you’re in heart-rhythm coherence, you perform at your best – what athletes call 
being in the zone. You feel confident, positive, focused and calm yet energized. 
Step One, “Heart Focus”: Focus your attention on the area around your heart, the area in the 
center of your chest. If you prefer, the first couple of times you try it, place your hand over the 
center of your chest to help keep your attention in the heart area. 
Step Two, “Heart Breathing”: Breathe deeply but normally and feel as if your breath is coming 
in and going out through your heart are. As you inhale, feel as if your breath is flowing in 
through the heart, and as you exhale, feel it leaving through this area. Breathe slowly and 
casually, a little deeper than normal. Continue breathing with ease until you find a natural inner 
rhythm that feels good to you. 
Step Three, “Heart Feeling”: As you maintain your heart focus and heart breathing, activate a 
positive feeling. Recall a positive feeling, a time when you felt good inside, and try to re-
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experience the feeling. One of the easiest ways to generate positive, heart-based feeling is to 
remember a special place you’ve been to or the love you feel for a close friend or family member 
or treasured pet. This is the most important step. 
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Appendix C 
Date Time Practice 
(no stress) 
How 
many 
minutes? 
SUDS 
before 
(0-10) 
SUDS 
after 
(0-10) 
Practice 
(during 
stress) 
How 
many 
minutes? 
SUDS 
before 
(0-10) 
SUDS 
after 
(0-10) 
Comments 
 a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
 
 
a.m. 
p.m. 
yes / no    yes/no     
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Appendix D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Summary of participant flow through the research protocol. 
 
 
Excluded  (n=297) 
   Not meeting inclusion criteria (n=  
248) 
   Declined to participate (n=49) 
Analyzed  (n=14) 
 Excluded from analysis (withdrew 
before post-test) (n=1) 
 Lost to follow-up (n=0) 
 Discontinued intervention (participant 
withdrew by not attending treatment 
sessions, no explanation provided) (n=1) 
Allocated to intervention (n=15) 
 Received allocated intervention 
(n=15) 
 
Lost to follow-up (n=0) 
 
Allocated to control condition (n=13) 
 
Analyzed  (n=13) 
 
 
Allocation 
Analysis 
Follow-Up 
Enrollment 
Assessed for eligibility (n=325) 
Randomized (n=28) 
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Figure 2. Repeated measures ANOVA for emWave performance points across session. Note: the 
last observation was carried forward for participants who completed only < 8 training sessions; 
Session 1 <  Session 2 < Session 3 < Sessions 4-8. 
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Figure 3. Interaction between Group and Session for pNN50 during stress, p < .05. 
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Appendix E 
Table 1. Summary of demographic information for study participants. 
  Treatment Control Overall 
Age  
in years 
Range 
Mean 
SD 
18-30 
22.29 
3.6 
19-29 
23.15 
4.06 
18-30 
22.54 
3.82 
Gender 
N (%) 
Male 
Female 
2 (14.3%) 
12 (85.7%) 
2 (15.4%) 
11 (84.6%) 
4 (14.8%) 
23 (85.2%) 
Race 
N (%) 
White 
Black 
Other 
14 (100%) 
0 
0 
11 (84.6%) 
1 (7.7%) 
1 (7.7%) 
26 (92.8%) 
1 (3.6%) 
1 (3.6%) 
Ethnicity 
N (%) 
Non-Hispanic 
Hispanic 
14 (100%) 
0 
11 (84.6%) 
2 (15.4%) 
26 (92.9%) 
2 (7.1%) 
Weight 
in pounds 
Range 
Mean 
SD 
102-227.4 
146.83 
34.93 
96-239.4 
156.19 
39.42 
96-239.4 
151.5 
36.07 
Height 
in inches 
Range 
Mean 
SD 
59-69 
64.59 
3.01 
58.75-73.75 
65.4 
4.48 
58.75-73.75 
64.96 
3.67 
BMI Range 
Mean 
SD 
18.21-37.13 
24.76 
5.77 
19.55-36.94 
25.53 
5.42 
18.21-37.13 
25.13 
5.51 
Parent income 
N (%) 
<24999 
25-34999 
35-49999 
50-74999 
75-99999 
100-149999 
150+ 
Missing 
1 (7.1%) 
0 
3 (21.4%) 
6 (42.9%) 
1 (7.1%) 
0 
1 (7.1%) 
2 (14.4%) 
2 (15.4%) 
2 (15.4%) 
4 (30.7%) 
1 (7.7%) 
2 (15.4%) 
1 (7.7%) 
1 (7.7%) 
0 
3 (11.1%) 
2 (7.4%) 
7 (25.9%) 
7 (25.9%) 
3 (11.1%) 
1 (3.6%) 
2 (7.4%) 
2 (7.4%) 
Student Status 
N (%) 
Undergraduate 
Graduate 
6 (42.9%) 
8 (57.1%) 
6 (46.2%) 
7 (53.8%) 
12 (42.9%) 
16 (57.1%) 
 
Number of 
Treatment 
Sessions 
N (%) 
4 
5 
6 
7 
8 
10 (71.4%) 
2 (14.3%) 
0 
0 
2 (14.3%) 
--- --- 
Note. Groups did not differ significantly on any demographic variable. 
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Table 2. Correlations among Physiological Outcomes and BMI, Age, and Sex at Baseline. 
 BMI Age Sex 
LF HRV    
Rest -0.10 0.10 0.17 
Mental Arithmetic    
Reactivity -0.06 0.41* -0.11 
Recovery -0.06 0.13 0.07 
Handgrip    
Reactivity -0.10 0.41* -0.13 
Recovery -0.12 0.06 0.11 
HF HRV 
   
Rest -0.17 0.21 0.34 
Mental Arithmetic    
Reactivity -0.26 0.31 0.14 
Recovery -0.13 0.17 0.37 
Handgrip    
Reactivity -0.18 0.30 0.01 
Recovery -0.24 0.20 0.32 
SDNN 
   
Rest -0.15 0.40* 0.17 
Mental Arithmetic    
Reactivity -0.22 -0.33 -0.01 
Recovery -0.15 0.19 0.26 
Handgrip    
Reactivity -0.17 0.54** 0.5 
Recovery -0.14 0.18 0.18 
pNN50 
   
Rest -0.25 0.33 0.31 
Mental Arithmetic    
Reactivity -0.20 .40* 0.01 
Recovery -0.16 0.28 0.32 
Handgrip    
Reactivity -0.15 0.33 0.20 
Recovery -0.35 0.31 0.24 
RMSSD 
   
Rest -0.21 0.36 0.30 
Mental Arithmetic    
Reactivity -0.21 0.41* 0.11 
Recovery -0.20 0.25 0.36 
Handgrip    
Reactivity -0.15 0.43* 0.15 
Recovery -0.24 0.29 0.30 
*p < .05. **p < .01. 
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Table 3. ANOVA for Evidence of Heart Rate Reactivity to Tasks. 
  F 
 Mean SD Group Period Group X Period 
Pre-Treatment      
Rest 77.85 9.98    
Mental Arithmetic 84.93 10.27 0.58
ns 
62.00*** 0.72
ns 
Handgrip 87.25 12.22 0.47
ns 
34.01*** 0.10
ns 
Post-treatment      
Rest 76.51 12.36    
Mental Arithmetic  81.48 10.61 0.04
ns 
37.14*** 1.34
ns 
Handgrip 83.84 12.81 0.41
ns 
23.21*** 0.03
ns 
***p < .001. 
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Table 4. ANCOVA for Evidence of Task Differences in Physiological Outcomes controlling for 
resting physiology and age. 
  F 
 EM Mean SE Group Task Group X Task 
HF HRV      
Pre-Treatment   0.03 1.34 1.10 
Mental Arithmetic 6.54 0.10 
 
 
 
Handgrip 6.18 0.16 
 
 
 
Post-treatment   0.68 0.02 1.64 
Mental Arithmetic  6.71 0.11 
 
 
 
Handgrip 6.41 0.20 
 
 
 
LF HRV      
Pre-Treatment   2.94 1.92 1.10 
Mental Arithmetic 7.16 0.09 
 
 
 
Handgrip 6.77 0.15 
 
 
 
Post-treatment   4.58* 0.86 3.41 
Mental Arithmetic  7.37 0.12 
 
 
 
Handgrip 7.10 0.12 
 
 
 
SDNN      
Pre-Treatment   0.56 4.05 0.03 
Mental Arithmetic 60.28 2.89 
 
 
 
Handgrip 62.55 3.58 
 
 
 
Post-treatment   3.43 0.18 1.32 
Mental Arithmetic  65.67 2.64 
 
 
 
Handgrip 68.56 3.36 
 
 
 
pNN50      
Pre-Treatment   0.08 0.44 0.05 
Mental Arithmetic 16.35 1.52 
 
 
 
Handgrip 15.21 2.12 
 
 
 
Post-treatment    6.34* 0.04 2.72 
Mental Arithmetic  21.33 21.33 
 
 
 
Handgrip 21.25 21.25 
 
 
 
RMSSD      
Pre-Treatment   0.65 0.21 0.08 
Mental Arithmetic 37.28 1.61 
 
 
 
Handgrip 37.58 2.75 
 
 
 
Post-treatment   0.45 3.05 4.04 
Mental Arithmetic  45.81 2.57 
 
 
 
Handgrip 45.15 3.07 
 
 
 
*p < .05. 
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Table 5. Repeated Measures ANCOVAs on measures of HRV between first and final treatment sessions 
for treatment participants, controlling for age. 
 First 
Session 
(EMM, SE) 
Final 
Session 
(EMM, SE) 
F 
HF HRV 7.00 (0.22) 6.61 (0.22) 0.00 
LF HRV 7.88 (2.5) 8.58 (0.25) 0.78 
SDNN 81.96 (7.60) 94.72 (7.70) 0.15
 
pNN50 26.7 (4.36) 28.09 (3.60) 0.02 
RMSSD 56.90 (5.55) 59.63 (3.52) 0.02 
Note: HF and LF values are natural log transformations of HRV data. 
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Table 6. Repeated Measures ANOVA on emWave performance points across treatment sessions for 
treatment participants. 
 Session 
 1 2 3 4 5 6 7 8 F 
emWave 
Performance 
Points 
2.27
a,b,c,d,e 
(0.65) 
2.90
a,b,c,d,e 
(0.94) 
3.55
a,b,c,d,e 
(1.21) 
4.09
a 
(1.14) 
4.27
b 
(0.90) 
4.27
c 
(0.90) 
4.27
d 
(0.90) 
4.27
e 
(0.90) 
32.90*** 
*** p < .001. 
Note: Means represent last observation carried forward for participants completing less than 8 sessions. 
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Table 7. ANCOVA for effects of Group and Session on tonic measures of HRV, controlling for age. 
 Pre-treatment Post-treatment F 
 EM Mean SE EM Mean SE Group Session Group X 
Session 
HF HRV     3.02
ns 
0.00
ns 
0.02
ns 
Treatment 6.64 0.29 6.86 0.28    
Control 6.13 0.30 6.28 0.29    
LF HRV     7.10
* 
0.18
ns 
0.00
ns 
Treatment 7.13 0.23 7.28 0.28    
Control 6.33 0.24 6.48 0.29    
SDNN     9.29
** 
0.44
ns 
0.38
ns 
Treatment 70.33 4.32 68.84 6.03    
Control 49.16 4.49 53.39 6.25    
pNN50     0.71
ns 
0.06
ns 
1.83
ns 
Treatment 25.86 4.42 23.38 5.21    
Control 15.85 4.58 23.52 5.41    
RMSSD     1.48
ns
 0.01
ns
 0.08
ns
 
Treatment 48.30 4.82 47.76 6.19 
 
 
 
Control 35.14 5.00 44.67 6.42    
* p < .05. ** p < .01. 
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Table 8. Group X Session ANCOVAs on HRV measures during stress, controlling for resting HRV and 
participant age. 
 Pre-test Post-test F 
 EM Mean SE EM Mean SE Group Session Group X 
Session 
HF HRV     0.16
ns 
1.07
ns 
2.09
ns 
Treatment 6.38 0.14 6.45 0.20    
Control 6.34 0.14 6.26 0.20    
LF HRV     3.18
ns 
4.11
ns 
3.80
ns 
Treatment 7.15 0.14 7.47 0.15    
Control 6.78 0.15 7.00 0.16    
SDNN     0.70
ns 
3.38
ns 
3.24
ns 
Treatment 64.12 4.29 72.13 4.04    
Control 58.82 4.48 63.27 4.21    
pNN50     2.51
ns 
9.65**
 
7.43*
 
Treatment 16.12 2.03 25.58 2.38    
Control 15.38 2.11 16.98 2.47    
RMSSD     1.84
ns
 6.35* 3.58
ns
 
Treatment 38.34 2.65 50.11 3.31 
 
 
 
Control 36.52 2.76 40.85 3.43    
*p < .05. **p < .01. 
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Table 9. Group X Session ANCOVAs on measures of HRV during recovery from stress, controlling for 
resting HRV and age. 
 Pre-test Post-test F 
 EM Mean SE EM Mean SE Group Session Group X 
Session 
HF HRV     2.77
ns 
2.38
ns 
0.30
ns 
Treatment 6.89 0.13 7.00 0.17    
Control 6.58 0.13 6.66 0.18    
LF HRV     3.36
ns
 0.01
ns 
1.58
ns 
Treatment 7.41 0.13 7.45 0.20    
Control 6.89 0.14 7.04 0.20    
SDNN     0.31
ns 
0.48
ns 
1.86
ns 
Treatment 75.90 4.33 72.66 4.13    
Control 65.28 4.51 74.87 4.29    
pNN50     3.08
ns 
0.04
ns 
0.01
ns 
Treatment 26.99 2.01 29.61 2.05    
Control 23.10 2.10 25.64 2.13    
RMSSD     2.36
ns
 0.05
ns
 0.06
ns
 
Treatment 51.91 3.77 55.16 2.94 
 
 
 
Control 46.40 3.93 49.79 3.05    
* p < .05 
Note: HF and LF values are natural log transformations of HRV data.
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Table 10. Exploratory Group X Session ANCOVAs on HRV measures during stress, controlling for 
resting HRV and participant age, and after excluding select treatment participants. 
 Pre-test Post-test F 
 EM Mean SE EM Mean SE Group Session Group X 
Session 
HF HRV     1.63
ns 
1.67
ns 
2.83
ns 
Treatment 6.38 0.14 6.67 0.18    
Control 6.34 0.14 6.45 0.19    
LF HRV     5.24* 5.36* 5.01* 
Treatment 7.15 0.14 7.48 0.15    
Control 6.78 0.15 7.00 0.16    
SDNN     1.67
ns 
5.00*
 
5.01*
 
Treatment 64.12 4.29 72.13 4.04    
Control 58.82 4.48 63.27 4.21    
pNN50     2.76
ns 
14.50**
 
11.64**
 
Treatment 16.12 2.03 25.58 2.38    
Control 15.38 2.11 16.98 2.47    
RMSSD     3.09
ns 
9.46** 6.20* 
Treatment 38.34 2.65 50.11 3.31 
 
 
 
Control 36.52 2.76 40.85 3.43    
*p < .05. **p < .01. 
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Table 11. Group X Session ANOVAs on self-report measures of affective response, stress, and 
psychological symptom distress. 
   Group  Session Group X 
Session 
  Mean (SD) F 
  Pre-Test Post-Test    
MAACLR Anxiety 
 
     
Baseline Treatment 
Control 
1.93 (2.56) 
0.77 (1.24) 
0.71 (1.07) 
0.38 (0.51) 
2.51 4.61* 1.24 
    
Task Treatment 
Control 
2.89 (1.69) 
2.38 (1.19) 
1.61 (1.06) 
2.08 (1.08) 
0.40 4.18 1.99 
    
MAACLR Depression 
 
     
Baseline Treatment 
Control 
0.86 (1.35) 
0.69 (1.03) 
0.50 (1.02) 
0.23 (0.60) 
0.34 7.82** 0.13 
    
Task Treatment 
Control 
1.00 (1.29) 
1.19 (1.20) 
0.71 (0.96) 
1.38 (1.18) 
2.25 0.35 1.51 
    
MAACLR Hostility 
 
     
Baseline Treatment 
Control 
0.36 (1.08) 
0.00 (0.00) 
0.29 (0.73) 
0.80 (0.28) 
1.51 0.15 0.26 
    
Task Treatment 
Control 
2.12 (1.69) 
1.88 (1.70) 
1.92 (2.34) 
1.81 (1.38) 
0.01 1.26 1.01 
    
MAACLR Positive Affect 
 
     
Baseline Treatment 
Control 
4.57 (2.65) 
6.15 (5.80) 
3.71 (2.70) 
6.46 (4.37) 
0.91 0.01 3.19 
    
Task Treatment 
Control 
0.73 (1.36) 
1.01 (1.14) 
1.19 (1.84) 
1.23 (1.13) 
0.26 1.10 0.65 
    
MAACLR Sensation Seeking     
Baseline Treatment 
Control 
0.43 (0.65) 
0.58 (1.44) 
0.21 (0.43) 
0.46 (6.6) 
0.34 0.16 1.12 
    
Arithmetic Treatment 
Control 
Treatment 
Control 
0.64 (1.08) 
0.15 (0.38) 
1.07 (1.14) 
1.23 (1.42) 
0.79 (0.89) 
0.46 (0.66) 
0.93 (0.83) 
0.85 (0.90) 
2.82 6.44* 0.04 
    
Handgrip 0.00 0.72 0.06 
    
PSS    
 Treatment 40.21 (9.33) 34.71 (8.99) 0.06 6.23* 2.18 
 Control 37.49 (6.40) 36.08 (5.82)    
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Table 11. (continued) 
   Group  Session Group X 
Session 
  Mean (SD) F 
  Pre-Test Post-Test    
BSI       
Somatization Treatment 
Control 
0.66 (0.58) 
0.54 (0.58) 
0.39 (0.63) 
0.40 (0.49) 
0.09 5.24* 0.54 
Obsessive-
Compulsive 
Treatment 
Control 
1.73 (1.05) 
1.27 (0.73) 
1.24 (1.15) 
1.19 (0.69) 
0.61 3.04 1.61 
Depression Treatment 
Control 
0.68 (0.70) 
0.77 (0.79) 
0.45 (0.69) 
0.50 (0.45) 
0.10 3.72 0.03 
Anxiety Treatment 
Control 
1.17 (0.80) 
0.55 (0.48) 
0.64 (0.79) 
0.45 (0.32) 
4.28* 5.44* 2.81 
Hostility Treatment 
Control 
0.63 (0.52) 
0.52 (0.51) 
0.51 (0.44) 
0.43 (0.45) 
0.30 2.23 0.03 
Phobic Anxiety Treatment 
Control 
0.29 (0.41) 
0.15 (0.45) 
0.24 (0.68) 
0.12 (0.24) 
0.75 0.48 0.48 
Paranoid 
Ideation 
Treatment 
Control 
0.51 (0.61) 
0.55 (0.49) 
0.44 (0.52) 
0.28 (0.41) 
0.14 2.69 0.94 
Psychoticism Treatment 
Control 
0.45 (0.52) 
0.46 (0.45) 
0.36 (0.54) 
0.34 (0.30) 
0.00 3.01 0.06 
Interpersonal 
Sensitivity 
Treatment 
Control 
0.75 (0.80) 
0.77 (0.73) 
0.77 (0.93) 
0.58 (0.62) 
0.10 0.54 0.78 
Additional Items Treatment 
Control 
0.93 (0.65) 
0.71 (0.64) 
0.61 (0.82) 
0.69 (0.63) 
0.08 2.12 1.67 
Global Severity 
Index 
Treatment 
Control 
0.80 (0.54) 
0.64 (0.42) 
0.57 (0.62) 
0.50 (0.32) 
0.43 5.51* 0.38 
* p < .05. ** p < .01. 
Note. No significant interactions between session and group observed (all ps > .05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
